

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Real-world Safety Profile of Zanubrutinib: a Disproportionality Analysis based on the FAERS Database

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-084991
Article Type:	Original research
Date Submitted by the Author:	06-Feb-2024
Complete List of Authors:	Wang, Jiangfeng; Ipharmacare Ltd, Department of Pharmaceutical Services Zheng, Xiaochun; Zhejiang Provincial People's Hospital, Pharmacy Lin, Jingyang; Hangzhou Medical College, Department of Cardiovascular Medicine Huang, Jinlong; Hangzhou Normal University; Hangzhou Medical College, Department of Pharmacy Zhang, Miaomiao; Hangzhou Normal University; Hangzhou Medical College, Department of Pharmacy Huang, Ping; Hangzhou Medical College, Department of Pharmacy Yang, Xiuli; Hangzhou Medical College, Department of Pharmacy
Keywords:	Adverse events < THERAPEUTICS, CLINICAL PHARMACOLOGY, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

1		
2		
4	1	Real-world Safety Profile of Zanubrutinib: a Disproportionality Analysis based
5	1	Real work Survey Frome of Zanasratinis, a Disproportionality rinarysis susea
6	r	on the FAFDS Detabase
7	2	on the FAEKS Database
8	3	
9 10	2	
10	1	Lingford Word MM Visselve 7hans MM? Lingvord Lin MM? Linger
12	4	Jangteng wang, MM, ^a Alaochun Zheng, MM, ^a Jingyang Lin, MM, ^a Jiniong Huang,
13		
14	5	BSc, ^{4,2} Miaomiao Zhang, BSc, ^{4,2} Ping Huang, MD, ^{2*} Xiuli Yang, MM, ^{2*}
15		
16	_	
17	6	
18		
19 20	_	
20	7	
22		
23	0	
24	8	Department of Pharmaceutical Services, Ipharmacare Ltd., Hangzhou, Zhejiang,
25		
26	9	China
27		
28		
29	10	² Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang
30 31		
32	11	Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College
33	11	riovinciari ecopie s riospitat(ritinated reopie s riospitat), riangznou incatear conege,
34	10	
35	12	Hangzhou, Zhejiang, China;
36		
37	12	311-art Conten Denertment of Condiscontrolog Medicine Zhaiine Deneringial Decelate
38	13	"Heart Center, Department of Cardiovascular Medicine, Znejlang Provincial People's
39		
40 41	14	Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou,
42		
43	15	Zheijang China 310014.
44		,,, ,
45		
46	16	⁴ School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China;
47		
48	17	
49 50	18	
51	19	
52	20	
53	20	
54	21 22	
55	22	
56	23	
57	24	
58 50	25	
59 60	26	
00	20	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Corresponding Author: Ping Huang, MD, Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, 158 Shangtang Rd, Gongsu District, Hangzhou, Zhejiang310014, China (Email: huangpwly@sina.com); Xiuli Yang, MM, Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 158 Shangtang Rd, Gongsu District, Hangzhou, Zhejiang310014, China (Email: xiuli8245@163.com) Abstract **Objective:** Zanubrutinib is a second-generation BTK inhibitor that has been approved for the treatment of several B-cell malignancies. The aim of this study was to evaluate adverse events (AEs) associated with zanubrutinib based on real-world data. Design: A disproportionality analysis was performed to identify the potential zanubrutinib-related AEs. Setting: The Food and Drug Administration Adverse Event Reporting System (FAERS) database from the fourth quarter of 2019 to the third quarter of 2023. Main outcome measures: The results of the disproportionality analyses were

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

 presented as reported odds ratios (ROR). When the lower limit of the 95% confidence interval (CI) for the ROR is greater than 1 and the number of AE reports is \geq 3, it indicates that the preferred term (PT) may be a positive AE signal. **Results:** A total of 846 AE reports with zanubrutinib as the primary suspect (PS) drug were obtained, with 2,826 AEs. A total of 74 positive PT signals were detected across 18 system organ classes (SOCs). The most significant signal for SOC was "Blood and lymphatic system disorders" (ROR = 2.8, 95% CI 2.3-3.3), while the most significant signal for PT was "Haemorrhage subcutaneous" (ROR = 190.8, 95% CI 128.0-284.5). Thirteen unexpected off-label AEs were also observed, such as abnormal hair texture, skin discolouration, hypernatraemia, pericardial effusion, and hypersomnia. The median time to onset of AEs associated with zanubrutinib was 51 days (interquartile range 13-192 days) and was consistent with the early failure model. Compared to zanubrutinib monotherapy, the combination of zanubrutinib and rituximab was associated with an increased risk of certain AEs, such as myelosuppression, pneumonia, leukopenia, decreased platelet counts, abdominal pain, anaemia, pancytopenia, and respiratory failure.

68 Conclusions: The results of the analysis provided valuable insights into the safety 69 profile of zanubrutinib-treated patients, which was helpful for clinical monitoring and 70 identifying potential AEs related to zanubrutinib.

71 Strengths and limitations of this study

BMJ Open

72	• The present study evaluated potential AEs related to Zanubrutinib based on the
73	Food and Drug Administration Adverse Event Reporting System (FAERS).
74	• Thirteen new AEs were found, such as abnormal hair texture, skin discolouration,
75	hypernatraemia, pericardial effusion, and hypersomnia.
76	• Zanubrutinib-related AEs are more likely to occur during the early period after the
77	initial dose and gradually decrease over time.
78	• The FAERS database is a voluntary reporting system that may have some
79	limitations, such as incomplete information and awareness bias.
80	
81	1. Induction
81 82	 Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of
81 82 83	 Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family.^{1,2} BTK
81 82 83 84	 Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family.^{1,2} BTK is mainly expressed in B lymphocytes, myeloid cells, and platelets.³ BTK is a vital
 81 82 83 84 85 	 Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family.^{1,2} BTK is mainly expressed in B lymphocytes, myeloid cells, and platelets.³ BTK is a vital signalling molecule in B-cell receptor (BCR) pathway and plays a crucial role in B-cell
 81 82 83 84 85 86 	 1. Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family.^{1,2} BTK is mainly expressed in B lymphocytes, myeloid cells, and platelets.³ BTK is a vital signalling molecule in B-cell receptor (BCR) pathway and plays a crucial role in B-cell differentiation, proliferation, and survival.² The treatment of B-cell malignancies has
 81 82 83 84 85 86 87 	 I. Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family.^{1,2} BTK is mainly expressed in B lymphocytes, myeloid cells, and platelets.³ BTK is a vital signalling molecule in B-cell receptor (BCR) pathway and plays a crucial role in B-cell differentiation, proliferation, and survival.² The treatment of B-cell malignancies has been greatly improved by the development of the inhibition of Bruton's tyrosine kinase.
 81 82 83 84 85 86 87 88 	1. Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family. ^{1,2} BTK is mainly expressed in B lymphocytes, myeloid cells, and platelets. ³ BTK is a vital signalling molecule in B-cell receptor (BCR) pathway and plays a crucial role in B-cell differentiation, proliferation, and survival. ² The treatment of B-cell malignancies has been greatly improved by the development of the inhibition of Bruton's tyrosine kinase.
 81 82 83 84 85 86 87 88 89 	1. Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family. ^{1,2} BTK is mainly expressed in B lymphocytes, myeloid cells, and platelets. ³ BTK is a vital signalling molecule in B-cell receptor (BCR) pathway and plays a crucial role in B-cell differentiation, proliferation, and survival. ² The treatment of B-cell malignancies has been greatly improved by the development of the inhibition of Bruton's tyrosine kinase. Since the approval of the first BTK inhibitor, ibrutinib, by the US Food and Drug Administration (FDA) in 2013, a variety of BTK inhibitors have been used clinically
 81 82 83 84 85 86 87 88 89 90 	1. Induction Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family. ^{1,2} BTK is mainly expressed in B lymphocytes, myeloid cells, and platelets. ³ BTK is a vital signalling molecule in B-cell receptor (BCR) pathway and plays a crucial role in B-cell differentiation, proliferation, and survival. ² The treatment of B-cell malignancies has been greatly improved by the development of the inhibition of Bruton's tyrosine kinase. Since the approval of the first BTK inhibitor, ibrutinib, by the US Food and Drug Administration (FDA) in 2013, a variety of BTK inhibitors have been used clinically to treat patients with B-cell malignancies over the past decade and have demonstrated

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

92	Zanubrutinib is a selective second-generation oral BTK inhibitor that covalently and
93	irreversibly binds to Cys-481 in the BTK ATP binding site. ¹⁰ By optimizing the
94	molecular structure, zanubrutinib improves BTK target selectivity and minimizes off-
95	target binding, resulting in more precise and sustained BTK inhibition. ^{10,11}
96	Zanubrutinib was first approved by the FDA in November 2019 to treat patients with
97	relapsed/refractory (R/R) mantle cell lymphoma (MCL). ¹⁰ The approval was based on
98	the results of two studies: phase 1/2 study BGB-3111-AU-003 (NCT02343120) and
99	phase 2 study BGB-3111-206 (NCT0320697). The trial NCT02343120 recruited 32
100	patients who had previously received treatment for MCL. The study achieved an overall
101	response rate (ORR) of 84%, with a complete response rate (CRR) of 29.7%. ¹² In the
102	phase II trial, 72 of 86 patients (84%) achieved an objective response (OR), with 59
103	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of
103 104	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months,
103 104 105	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment
103 104 105 106	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström macroglobulinemia (WM) and in September 2021 for marginal zone
103 104 105 106 107	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström macroglobulinemia (WM) and in September 2021 for marginal zone lymphoma (MZL). ¹¹ In January 2023, zanubrutinib was granted FDA approval for the
103 104 105 106 107 108	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström macroglobulinemia (WM) and in September 2021 for marginal zone lymphoma (MZL). ¹¹ In January 2023, zanubrutinib was granted FDA approval for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma
103 104 105 106 107 108 109	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström macroglobulinemia (WM) and in September 2021 for marginal zone lymphoma (MZL). ¹¹ In January 2023, zanubrutinib was granted FDA approval for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) based on the results of the ALPINE and SEQUOIA trials. The ALPINE study,
103 104 105 106 107 108 109 110	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström macroglobulinemia (WM) and in September 2021 for marginal zone lymphoma (MZL). ¹¹ In January 2023, zanubrutinib was granted FDA approval for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) based on the results of the ALPINE and SEQUOIA trials. The ALPINE study, an open-label, multicentre, randomized, phase III clinical trial evaluating the efficacy
103 104 105 106 107 108 109 110 111	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström macroglobulinemia (WM) and in September 2021 for marginal zone lymphoma (MZL). ¹¹ In January 2023, zanubrutinib was granted FDA approval for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) based on the results of the ALPINE and SEQUOIA trials. The ALPINE study, an open-label, multicentre, randomized, phase III clinical trial evaluating the efficacy and safety of zanubrutinib versus ibrutinib in 652 patients with R/R CLL/SLL, showed
 103 104 105 106 107 108 109 110 111 112 	(68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström macroglobulinemia (WM) and in September 2021 for marginal zone lymphoma (MZL). ¹¹ In January 2023, zanubrutinib was granted FDA approval for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) based on the results of the ALPINE and SEQUOIA trials. The ALPINE study, an open-label, multicentre, randomized, phase III clinical trial evaluating the efficacy and safety of zanubrutinib versus ibrutinib in 652 patients with R/R CLL/SLL, showed that zanubrutinib was superior to ibrutinib in terms of ORR and PFS. ¹⁴ The SEQUOIA

Page 7 of 33

BMJ Open

or bendamustine plus rituximab, showed a significant improvement in progression-free
survival with zanubrutinib compared to bendamustine-rituximab.¹⁵

Although BTK inhibitors have shown impressive efficacy and activity, they still require careful attention to safety and monitoring for some unique toxic reactions.¹⁶ Pooled data from six zanubrutinib monotherapy trials involving 779 patients showed that 98% of patients experienced at least one adverse event (AE).¹⁷ The most common nonhematologic AEs were upper respiratory tract infection, rash, bruising, musculoskeletal pain, diarrhoea, cough and pneumonia, urinary tract infection, fatigue, hematuria, constipation, headache, pyrexia, hypertension, and nausea. However, clinical trials are conducted under strict limitations, and AEs of zanubrutinib observed in clinical trials may not fully reflect all AEs observed in clinical practice. Therefore, a comprehensive assessment of the post-marketing safety of zanubrutinib based on real-world data is needed.

127 The FDA Adverse Event Reporting System (FAERS) is a free database of spontaneous 128 AE reports submitted by manufacturers, healthcare professionals, individual patients 129 and others. FAERS is widely used in signal mining studies of AEs, which can 130 effectively monitor and evaluate the post-marketing safety of drugs.¹⁸ In the present 131 study, we used data mining of FAERS to retrospectively identify and investigate the 132 signals of zanubrutinib-associated ADRs. Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

2. Methods

2.1. Data Sources and Cleaning

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

> This disproportionality analysis was performed to analyze zanubrutinib-related AEs using data from the FAERS database. Data ranging from the fourth quarter of 2019 (when zanubrutinib was approved by the FDA) to the third guarter of 2023 were selected for analysis. FAERS data is composed of seven datasets: demographic and administrative information (DEMO), drug information (DRUG), adverse event information (REAC), drug therapy start dates and end dates (THER), indications for the reported drugs (INDI), patient outcomes information (OUCT), and reported sources (RPSR). PRIMARYID linked the same AE report across different datasets. Data units from different seasons were combined using R software. Prior to statistical analysis, we performed deduplication based on the following standards: if the PRIMARYIDs were identical, the most recent FDA DT was chosen, if both the PRIMARYIDs and FDA DTs were identical, the lower PRIMARYIDs were deleted.¹⁹

2.2. Adverse Event Identification and Mining

Various drug names including "zanubrutinib", "BGB 3111" and "Brukinsa" were used in the search for zanubrutinib. In the FAERS database, there are four codes for the role of drugs in reported adverse events: Primary Suspect (PS), Secondary Suspect (SS), Concomitant (C), and Interacting (I). Only reports that document zanubrutinib as the role code of PS were selected for analysis to improve accuracy. AE reports in the FAERS database are coded using Preferred Terms (PTs) from the Medical Dictionary for Regulatory Activities (MedDRA). For the present analysis, the PTs and System Organ Classes (SOC) were categorized according to MedDRA version 26.1. The European Union Drug Regulating Authorities Pharmacovigilance of Important Medical

BMJ Open

Events (IME) was utilized to evaluate serious adverse events. Additionally, clinical characteristics such as gender, age, outcomes of AEs, country of report, and reporter occupation were gathered.

A disproportionality signal occurs when the reported incidences of AEs for a targeted drug are higher than those in the background data. Reporting odds ratios (ROR) were used in our analysis to identify potential signals that may indicate an increased risk of drug-associated AEs for zanubrutinib. The ROR was calculated using a two-by-two contingency table that contrasted the reported event counts for the target medication with those of other background drugs.²⁰ The calculation formula of ROR is shown in Supplementary Table S1. The magnitude of the ROR value represents the strength of the association between the reported drug and specific AE. The signal of PT was considered positive if the lower limit of the 95% confidence interval (CI) for ROR was greater than 1 and the number of AE reports was ≥ 3.20 PTs related to the progression of disease, medication errors, and surgical operations were excluded.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2.3. Time-to-onset analysis

173 The time-to-onset of AEs was calculated by subtracting the zanubrutinib initiation date 174 (START_DT) from the AE onset date (EVENT_DT). AE reports with incomplete dates, 175 no dates, and incorrectly formatted dates were excluded. The time-to-onset was 176 described using the Weibull shape parameter test and the proportion of events by time. 177 The Weibull distribution is a continuous probability distribution that is described by a 178 scale parameter (α) and a shape parameter (β). The time-to-onset analysis predicted the 179 risk of AEs over time-based on the shape parameter. The predicted results were

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

180 classified into three categories: "early failure", "random failure", or "wear-out failure".
181 If both the shape parameter and its 95% CI were less than 1, the risk of AE is estimated
182 to decrease over time, which is referred to as early failure. If the shape parameter is
183 equal to or close to 1 and its 95% CI encompasses 1, the risk of AE is considered not
184 to change over time, which is referred to as ' random failure '. If both the shape
185 parameter and its 95% CI were above 1, the risk of AE is predicted to increase gradually,
186 which is referred to as ' wear-out failure'.²¹

7 2.4. Drug combination analysis

The safety of zanubrutinib in combination with other drugs was also investigated. First, the drugs used in combination were retrieved from all reports that included zanubrutinib (PS, SS, I, and C) and ranked according to the number of cases of combination. Preliminary results showed that the drug with the highest number of combinations with zanubrutinib was rituximab. Further disproportionality analyses were then performed on the drugs with the highest number of combination cases. In the disproportionality analyses for combination therapy, target drug cases were defined as zanubrutinib (PS) + rituximab (any role code) or rituximab (PS) + zanubrutinib (any role code), and background data were defined as zanubrutinib (PS) without rituximab. When the ROR signal was positive and p-value < 0.05 (chi-squared test), this indicated that the combination therapy was more likely to cause a specific AE than zanubrutinib monotherapy.²²

200 R software version 4.3.2 was used for all data cleaning, mining, statistical analyses, and201 graphs.

202	3. Result
203	3.1. Population Characteristics
204	A total of 7,575,864 AE reports were recorded in the FAERS database between October
205	2019 and September 2023 (Supplementary Figure S1). After removing duplicates, there
206	were 846 AE reports associated with zanubrutinib as the PS, documenting a total of
207	2,826 zanubrutinib-related AEs. Patient characteristics are summarized in Table 1. In
208	the included cases, hospitalization - initial or prolonged was the most common severe
209	outcome, accounting for 25.7% (218/848). AEs with zanubrutinib resulted in 64 deaths
210	(7.5%). Approximately 60% of the reports were submitted by healthcare professionals,
211	such as physicians (33.0%), pharmacists (11.2%), and other healthcare professionals
212	(14.4%). The majority of AEs were reported from the United States (61.7%), followed
213	by China (16.6%).
214	A total of 166 AEs were reported in the FAERS for the combination of zanubrutinib
215	and rituximab, with either zanubrutinib or rituximab as the PS. The most frequent
216	severe outcome of adverse events remained the hospitalization - initial or prolonged.
217	The majority of the reports (62.0%) originated from China.
218	3.2. Signal of System Organ Classifications

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

AEs induced by zanubrutinib were found in 26 different organ systems (Figure 1). Among them, six significant SOCs were identified, including "Blood and lymphatic system disorders", "Skin and subcutaneous tissue disorders", "infections and infestations", "Investigations", "Injury, poisoning and procedural complications", and "Cardiac disorders".

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3.3. Signal of preferred terms

A total of 74 positive PT signals belonging to 18 SOCs were detected in our analysis. Several positive signals that may be associated with lymphoma complications, such as "blood lactate dehydrogenase increased", "splenomegaly", "blood immunoglobulin M increased", and "lymphadenopathy" were not taken into account. The top 25 AEs with the highest ROR for zanubrutinib are displayed in Figure 2, and the full list of positive PT signals based on the SOCs is listed in Supplementary Table S2. The strongest AE signal was the PT of "Haemorrhage subcutaneous" (ROR = 190.8, 95%CI 128.0-284.5), followed by "Penile haemorrhage" (ROR = 112.6, 95%CI 35.9-352.6). Most of the positive signals were reported in previous clinical studies or listed on the label for zanubrutinib. Nevertheless, thirteen positive signals, such as skin discolouration, abnormal hair texture, hypernatremia, pericardial effusion, and hypersomnia, were not mentioned on the label.

In addition, 20 of the 74 positive PT signals were considered serious AEs according to the IME list (Supplementary Figure S2). The largest number of cases occurred in myelosuppression, with 39 reported cases.

3.4. Results for the time-to-onset analysis

After excluding reports with incomplete dates, a total of 223 reports were included in the time-to-onset analysis, with a median onset time of 51 days (interquartile range [IQR] 13-192). Out of the 223 reports, 91 (40.8%) occurred during the first month of zanubrutinib treatment, and a total of 164 (73.5%) occurred within six months of the initial dose (Figure 3). A scale parameter of 123.7 (95% CI 95.0-152.4) and a shape

BMJ Open

parameter of 0.60 (95% CI 0.54-0.66) were obtained when fitting the time-to-onset to
the Weibull distribution. It indicated that the risk of AEs associated with zanubrutinib
should be referred to as 'early failure', and that the likelihood of experiencing AEs
decreases over time.

250 3

3.5. Results for the combination analysis

The five most commonly combined drugs with zanubrutinib in all reports from Q4 2019 through Q3 2023 in the FAERS database were rituximab (n = 373), cyclophosphamide (n = 231), prednisone (n = 216), obinutuzumab (n = 205), and vincristine (n = 114). A disproportionality analysis was conducted to investigate the impact of co-administering rituximab on the safety profile of zanubrutinib. The results showed that 10 AEs (Figure 4), such as myelosuppression, pneumonia, leukopenia, and platelet count decreased, may be more likely to occur in patients treated with rituximab + zanubrutinib than in patients treated with zanubrutinib alone.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

259 4. Discussion

BTK inhibitors have demonstrated superior clinical efficacy and tolerability in patients with B-cell malignancies in comparison to standard chemotherapy and immunotherapy regimens. ²³ The AEs related to BTK inhibitors were mostly classified as grade 1-2, with a low frequency of grade \geq 3 AEs.²⁴ The rate of treatment termination due to AEs was relatively low. The first-generation BTK inhibitor ibrutinib displayed significant off-target effects. It inhibited other kinases non-specifically and bound to other signalling channel proteins, leading to a range of adverse effects. In contrast, zanubrutinib was a next-generation BTK inhibitor that had improved specificity and

Page 14 of 33

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

off-target effects, resulting in a lower incidence of treatment-related adverse events.^{8,9}
Nonetheless, patients treated with zanubrutinib may experience unique AEs that require
close monitoring to ensure optimal efficacy.

A comprehensive disproportionality analysis of the safety profile of zanubrutinib was
conducted based on post-marketing data from the FAERS database. In the almost four
years since zanubrutinib was marketed, the FAERS database has documented 846 AE
reports where zanubrutinib was the primary suspect. A total of 74 positive PT signals
were identified, which were involved in 18 of the SOCs.

The disproportionality analysis revealed that the AEs with the most significant signal at the SOC levels were related to 'blood and lymphatic system disorders'. Hematologic toxicity, including neutropenia, thrombocytopenia, and anaemia, was one of the most common adverse events (AEs) associated with zanubrutinib. Neutropenia was one of the few adverse events that occurred more frequently with zanubrutinib than with ibrutinib (29% vs. 13%; hazard ratio, 2.18; 95% CI, 1.15 to 4.12).9 The various complex mechanisms of immune dysregulation resulting from B lymphocytoma may contribute to the hematologic toxicity.²³ Severe hematologic toxicity may lead to dose adjustment or discontinuation of zanubrutinib therapy.^{8,9} The most common cause of zanubrutinib dose reductions is neutropenia.¹⁷ Jiang et al.²⁵ developed an XGBoost model to predict the severe haematological toxicity of BTK inhibitors. The XGBoost model was constructed based on ten parameters: leukocytes, neutrophils, erythrocytes, platelets, fibrinogen, total albumin, aspartate aminotransferase, lactate dehydrogenase, gender, and the type of BTK inhibitor. Among them, lactate dehydrogenase, neutrophils,

BMJ Open

BTK inhibitor (ibrutinib), and gender (female) were positively correlated with the
outcome, while other factors were negatively correlated with the outcome. The
XGBoost model is available online for clinical use.

Of the 74 positive PT signals we obtained, up to 18 were associated with haemorrhages, such as eye haemorrhage, haematemesis, subdural hematoma, haemarthrosis, haemorrhage intracr, haematuriaanial, penile haemorrhage, ecchymosis, and skin haemorrhage. Bleeding was a frequently observed AE in patients treated with zanubrutinib, and the majority of these AEs were mild (grade ≤ 2).^{8,17} Clinical studies have shown that bleeding events of any grade occurred in 4.4%-66.0% of patients treated with zanubrutinib, with major bleeding occurring in 0.3%-3.5%. 8,9,17,26 Bleeding was more likely to occur in patients ≥ 75 years. ¹⁷ Patients who suffered a bleeding event of \geq grade 3 needed to discontinue zanubrutinib permanently unless the risk of rebleeding was deemed acceptable.²³ Studies have shown an increased risk of bleeding when BTK inhibitors are combined with anticoagulants or antiplatelet agents.23

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Studies on the pathophysiology of zanubrutinib-associated bleeding are limited. Currently, the mechanisms of haemorrhage associated with BTK inhibitors are mainly explored based on ibrutinib.^{3,27} It has been suggested that the risk of bleeding associated with BTK inhibitors may be due to both on- and off-target effects. BTK and TEC interfered with collagen-induced platelet activation by regulating the platelet transmembrane receptors, including the platelet glycoprotein VI (GPVI) and the C-type lectin-like receptor 2 (CLEC-2). GPVI is the main signalling receptor for collagen. The

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

binding of collagen to GPVI triggers the platelet activation cascade.²⁸ CLEC-2 activates signal transduction via tyrosine phosphorylation of a single YXXL motif in its cytoplasmic tail, which triggers the platelet activation cascade.²⁹ BTK inhibitors irreversibly inhibit the BTK and TEC leading to the inhibition of GPVI- and CLEC-2mediated platelet activation.^{3,27} In addition to GPVI and CLEC-2 signalling, inhibition of the GPIb and α IIb β 3-integrin pathways may also contribute to bleeding caused by BTK inhibitors.^{3,16}

Patients treated with zanubrutinib were at high risk of infection due to immunosuppression. The infectious event with the most cases reported in the FAERS database was urinary tract infection (n = 19; ROR 2.4; 95% CI 1.6 to 3.8). Opportunistic infections, including fungal pneumonia (ROR=23.7, 95% CI 10.6-53.0), cryptococcal meningitis (ROR=40.1, 95% CI 12.9-124.9), and pneumocystis carinii pneumonia (ROR=15.5, 95% CI 1.8-17.2), were detected. The pooled safety analysis revealed that infections had the highest incidence of AEs, with a 76% occurrence rate.¹⁷ Additionally, serious infections were reported in 27% of cases. The ALPINE trial showed that infectious events were the most common AEs leading to discontinuation.⁸ The mechanism of increased susceptibility to infection is complex, primarily involving the effect of BTK inhibitors on the immune system.²⁶ BTK played a crucial role in detecting a broad spectrum of microbes via various Toll-like receptors.³⁰ BTK inhibitors may interfere with the sensing of pathogens. In addition, neutrophils are a crucial component of the human immune system, serving as a key defender against pathogenic pathogens. However, neutropenia is a common AE experienced by patients receiving zanubrutinib.

Page 17 of 33

BMJ Open

Unexpected and significant PT signals such as abnormal hair texture, skin discolouration, hypernatremia, pericardial effusion, hypersomnia, intestinal perforation, and blood iron decrease were detected in our analysis. All of the unexpected and novel AEs need to be further confirmed in future studies and require vigilance in clinical practice. Hair changes were thought to be one of the skin toxicities of ibrutinib, but have not been reported in zanubrutinib-treated patients. A meta-analysis of 32 clinical trials evaluated the dermatologic toxicity of ibrutinib.³¹ Among the 32 clinical trials included, two of the phase II clinical studies for the treatment of CLL/SLL reported hair changes associated with ibrutinib (7.9%; 95% CI, 0.0-21.3%). A pharmacovigilance analysis of ibrutinib and acalabrutinib using the FAERS database identified 84 cases of ibrutinib-associated hair changes by December 2021 (ROR = 108.7, 95% CL 85.0-139.1).³² However, no positive signal was found for acalabrutinib. The proteins in the keratinocytes of the hair contained an abundance of sulfur-containing amino acids that formed disulfide bonds, which were important for the tensile strength and structural integrity of the hair.³³ The covalent binding of the BTK inhibitors to cysteine residues in the BTK active site disrupted the disulfide bond between cysteine residues, which may lead to hair changes.³⁴ Skin discolouration, another unexpected dermatologic toxicity that we detected, manifested primarily as abnormal skin pigmentation. However, it was not detected in either ibrutinib or acalabrutinib.^{31,32,34} Our analysis revealed that the median time to onset of all adverse events (AEs) associated with zanubrutinib was 51 days (IQR 13-192), with 73.5% of cases occurring

355 within 6 months of exposure to the drug. This onset time appears to be shorter than that

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

of most AEs reported in clinical studies. Clinical studies have shown that bleeding
events, infectious events, neutropenia, thrombocytopenia, anemia, and atrial fibrillation
had a median time to onset of 52 days (IQR 15-167), 89 days (IQR 29-199), 86 days
(IQR 45-339), 84 days (IQR 28-343), 102 days (IQR 64-109), and 183 days (IQR 36622), respectively.^{17,35}

As the combination regimens of zanubrutinib are gaining clinical interest, we conducted a further search in the FAERS database for adverse events (AEs) associated with these combinations.³⁶⁻³⁹ According to our analysis, rituximab was the most frequently used agent in combination with zanubrutinib, with a total of 373 reports. Out of these cases, 166 were identified as the PS for either zanubrutinib or rituximab. AEs that occur at higher risk in patients treated with zanubrutinib plus rituximab include myelosuppression, pneumonia, leukopenia, decreased platelet count, abdominal pain, anaemia, pancytopenia, respiratory failure, pneumonitis, and elevated blood lactate dehydrogenase. This is similar to the results of a phase I clinical study, which demonstrated that the combination of zanubrutinib and rituximab resulted in AEs with an incidence of $\geq 10\%$, including leukopenia, neutropenia, anaemia, upper respiratory tract infection, elevated liver enzymes, hematuria, pneumonitis, decreased platelet count, and purpura.³⁷

Our study existed several limitations that were inherent to data mining research with the FAERS database. First of all, The FAERS is a self-reporting database that inevitably contains omissions, incomplete information, arbitrary reporting, misreporting, and misinterpreted relationships, which can lead to potentially biased results in

BMJ Open

disproportionality analyses. Secondly, the disproportionality analysis only revealed a statistical correlation, rather than a clear causal association between the target drug and the specific AEs. Therefore, further causal evaluation is required, which may include reviewing drug labels, literature reports, expert opinions, or conducting well-designed clinical trials. However, signals identified through big data analytics from postmarketing drug surveillance remain clinically significant in suggesting potential drug risk.

5. Conclusion

The safety profile of zanubrutinib was analysed in the real world, revealing a strong association with haematological toxicity, bleeding, infection, and other adverse events. These findings were consistent with the label and confirmed the reliability of this study. The analysis showed that zanubrutinib may be susceptible to AEs not listed on the label, such as abnormal hair texture, skin discolouration, hypernatraemia, pericardial effusion, and hypersomnia. The time-of-event analysis showed that zanubrutinib-related AEs were characterised by an early failure profile, indicating that the risk of zanubrutinib-related AEs was higher in the early stage of treatment, with a decreasing risk over time. Furthermore, it has been demonstrated that the combination of zanubrutinib and rituximab increases the risk of several AEs, such as myelosuppression, pneumonia, leukopenia, decreased platelet counts, abdominal pain, anaemia, pancytopenia and respiratory failure compared to zanubrutinib alone. Our study provides important evidence for the clinical safety of zanubrutinib.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

400 Authors' contributions

401 Contributors JW and XY conceived and designed the study. XZ, JL, JH and MZ 402 performed the data extraction and data analyses. JW drafted the manuscript. PH and 403 XY revised the manuscript. JW is the guarantor of the manuscript and accepts full 404 responsibility for the work. All authors have read and approved the version of the 405 manuscript submitted for publication.

- **Competing interests**
 - 407 All authors declare that they have no competing interests.

408 Funding

409 This study was supported by the Research Program for Medicine and Health Science 410 and Technology of Zhejiang Province (2022KY585, 2024KY761), Zhejiang 411 Pharmaceutical Association Foundation Project (2020zyy22), Zhejiang Medical 412 Doctors Association Foundation Project (YS2022-3-009). Role of the funder: The 413 funders had no role in the study, including collection, analysis, and interpretation of the 414 data, writing of the manuscript, and the decision to submit the manuscript for 415 publication.

Patient and public involvement

417 Patients and/or the public were not involved in the design, conduct, reporting, or418 dissemination plans of this research.

419 Ethics approval

420 Patient information in the FAERS database is anonymized. Therefore, ethical approval
421 according to the Declaration of Helsinki is not required.

422 Data sharing statement

423 The datasets generated during and/or analysed during the current study are available424 from the corresponding author upon reasonable request.

426 Acknowledgements

427 Not applicable.

53	430		
54	450		
55			
56	431	Reference	
57			

Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. *Cancer journal*. Nov/Dec 2019;25(6):386-393.

BMJ Open

1			
2			
3	434	2.	Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B
4 5	435		cells and malignancies. <i>Molecular cancer</i> . Feb 19 2018;17(1):57.
6	436	3.	von Hundelshausen P, Siess W. Bleeding by Bruton Tyrosine Kinase-Inhibitors:
7	437		Dependency on Drug Type and Disease. Cancers. Mar 4 2021;13(5).
8	438	4.	Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to
9 10	439		six years of follow-up on ibrutinib in patients with previously treated chronic
11	440		lymphocytic leukemia or small lymphocytic lymphoma American journal of
12	441		hematology Dec 2019:94(12):1353-1363
13	442	5	Mato AR Shah NN Jurczak W et al Pirtobrutinib in relansed or refractory B-
14	443	5.	cell malignancies (BRUIN): a phase 1/2 study Langet Mar 6
16	113		2021·307(10277)·802_001
17	444	6	2021,577(10277).092-901. Degars KA Thompson BA Allan IN at al Phasa II study of acalebrutinih in
18	445	0.	Rogers KA, Information FA, Anan JN, et al. Flase II study of acataolutino in
19 20	440		lockensis University for 1 2021-10((0)-22(4,2272)
21	44 /	-	leukemia. Haematologica. Sep 1 2021;106(9):2364-2373.
22	448	7.	Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study
23	449		of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's
24 25	450		macroglobulinemia. <i>Cancer science</i> . Sep 2020;111(9):3327-3337.
26	451	8.	Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib Versus Ibrutinib in
27	452		Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic
28	453		Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of
29	454		clinical oncology : official journal of the American Society of Clinical Oncology.
30 31	455		Feb 10 2023;41(5):1035-1045.
32	456	9.	Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs
33	457		ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study.
34 25	458		<i>Blood</i> . Oct 29 2020:136(18):2038-2050.
35 36	459	10	Sved YY Zanubrutinib. First Approval Drugs. Jan 2020:80(1):91-97
37	460	11	Tam CS Munoz IL Seymour IF Opat S Zanubrutinib: past present and future
38	461		Blood cancer journal Sep 11 2023:13(1):141
39	462	12	Tam CS Onat S Simpson D et al Zanubrutinib for the treatment of relansed
40 41	462	12.	or refractory mantle call lymphome. <i>Blood advances</i> Jun 22 2021:5(12):2577
42	403		of reflactory manue cen tymphoma. <i>Biobu uuvunces</i> . Juli 22 2021,5(12).2577-
43	404	12	2385. Come V. Zhang V. Zhang D. et al. Treatment of Definite south Delanged on
44	465	13.	Song Y, Zhou K, Zou D, et al. Treatment of Patients with Relapsed of
45 46	466		Refractory Mantie-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of
40	467		Bruton's Tyrosine Kinase. Clinical cancer research : an official journal of the
48	468		American Association for Cancer Research. Aug 15 2020;26(16):4216-4224.
49	469	14.	Wolska-Washer A, Robak T. Zanubrutinib for the treatment of lymphoid
50 51	470		malignancies: Current status and future directions. Frontiers in oncology.
52	471		2023;13:1130595.
53	472	15.	Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and
54	473		rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic
55 56	474		lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. The Lancet.
סכ 57	475		Oncology. Aug 2022;23(8):1031-1043.
58	476	16.	Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors.
59	477	-	Hematology, American Society of Hematology, Education Program Dec 4
60	- , ,		

3	478		2020;2020(1):336-345.
4 5	479	17.	Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of
6	480		zanubrutinib monotherapy in patients with B-cell malignancies. <i>Blood advances</i> .
7	481		Feb 22 2022;6(4):1296-1308.
8	482	18	Beninger P Murray M Review of FDA Amendments Act Section 921
9 10	483	10.	Experience in Posting Data-mining Results from the FAFRS Database <i>Clinical</i>
10	197		thereneuties. Eab 2021:42(2):280-205
12	404	10	Show V. Ha V. Liv V. Wy D. Zhang O. A. Daal Ward Diagram articulative Analysis
13	485	19.	Shu Y, He X, Liu Y, Wu P, Zhang Q. A Real-world Disproportionality Analysis
14	486		of Olaparib: Data Mining of the Public Version of FDA Adverse Event
15 16	487		Reporting System. <i>Clinical epidemiology</i> . 2022;14:789-802.
10	488	20.	Liu P, He M, Xu X, He Y, Yao W, Liu B. Real-world safety of Lacosamide: A
18	489		pharmacovigilance study based on spontaneous reports in the FDA adverse
19	490		event reporting system. Seizure. Aug 2023;110:203-211.
20	491	21.	Mazhar F, Battini V, Gringeri M, et al. The impact of anti-TNFalpha agents on
21	492		weight-related changes: new insights from a real-world pharmacovigilance
23	493		study using the FDA adverse event reporting system (FAERS) database. <i>Expert</i>
24	494		opinion on biological therapy. Sep 2021:21(9):1281-1290.
25	495	22	Li Z. Zou W. Yuan I. Zhong Y. Fu Z. Gender differences in adverse events
26 27	496	<i></i> .	related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse
27 28	490		event reporting system Export opinion on drug safety Jul 31 2023:1.8
29	497	22	Song V. Wu SL Shon Z at al. Chinaga awart consongue on Druton turogina
30	498	23.	Song I, wu SJ, Shen Z, et al. Chinese expert consensus on Bruton tyrosine
31	499		kinase inhibitors in the treatment of B-cell malignancies. Experimental
32	500		hematology & oncology. Oct 16 2023;12(1):92.
34	501	24.	O'Brien SM, Brown JR, Byrd JC, et al. Monitoring and Managing BTK
35	502		Inhibitor Treatment-Related Adverse Events in Clinical Practice. Frontiers in
36	503		oncology. 2021;11:720704.
37	504	25.	Jiang D, Song Z, Liu P, Wang Z, Zhao R. A prediction model for severe
38 30	505		hematological toxicity of BTK inhibitors. Annals of hematology. Oct
40	506		2023;102(10):2765-2777.
41	507	26.	Estupiñán HY, Berglöf A, Zain R, Smith CIE. Comparative Analysis of BTK
42	508		Inhibitors and Mechanisms Underlying Adverse Effects. (2296-634X (Print)).
43	509	27	Shatzel JJ Olson SR Tao DL McCarty OJT Danilov AV DeLoughery TG
44 45	510	<i>_</i> /.	Ibrutinib-associated bleeding: nathogenesis management and risk reduction
46	511		strategies Journal of thrombosis and harmostasis · ITH May 2017:15(5):835-
47	512		947
48	512	20	047. Desere I. Wetern CD. Nieserendt D. Ernstissel significants of the platelet
49 50	513	28.	Rayes J, watson SP, Nieswandt B. Functional significance of the platelet
50	514		immune receptors GPVI and CLEC-2. The Journal of clinical investigation. Jan
52	515		2 2019;129(1):12-23.
53	516	29.	May F, Hagedorn I, Pleines I, et al. CLEC-2 is an essential platelet-activating
54	517		receptor in hemostasis and thrombosis. <i>Blood</i> . Oct 15 2009;114(16):3464-3472.
55	518	30.	Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton's
57	519		Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Frontiers in
58	520		immunology. 2017;8:1454.
59	521	31.	Nocco S, Andriano TM, Bose A, et al. Ibrutinib-associated dermatologic
60		-	, , , ,

1			
2	500		
4	522		toxicities: A systematic review and meta-analysis. Critical reviews in
5	523		oncology/hematology. Jun 2022;1/4:103696.
6	524	32.	Wan Q, Li Q, Lai X, Xu T, Hu J, Peng H. Data mining and safety analysis of
/ 8	525		BTK inhibitors: A pharmacovigilance investigation based on the FAERS
9	526		database. Frontiers in pharmacology. 2022;13:995522.
10	527	33.	de Sa Dias TC, Baby AR, Kaneko TM, Robles Velasco MV.
11	528		Relaxing/straightening of Afro-ethnic hair: historical overview. Journal of
12	529		cosmetic dermatology. Mar 2007:6(1):2-5.
13 14	530	34.	Bitar C. Farooqui MZ. Valdez J. et al. Hair and Nail Changes During Long-term
15	531		Therapy With Ibrutinib for Chronic Lymphocytic Leukemia JAMA
16	532		dermatology Jun 1 2016:152(6):608-701
17	522	25	Oper S. Tedeschi A. Hu, P. et al. Safety and officeasy of zepubrutinib in
18	555	55.	opat S, Tedeseni A, Tiu B, et al. Safety and enfeaty of Zandorutinio in
19 20	534		relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA
20	535		study. Blood advances. Nov 28 2023; /(22):6801-6811.
22	536	36.	Soumeral JD, Mato AR, Dogan A, et al. Zanubrutinib, obinutuzumab, and
23	537		venetoclax with minimal residual disease-driven discontinuation in previously
24 25	538		untreated patients with chronic lymphocytic leukaemia or small lymphocytic
25 26	539		lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology.
27	540		Dec 2021;8(12):e879-e890.
28	541	37.	Zhang Q, Tao R, Li Z, et al. A phase II study of Zanubrutinib in combination
29	542		with rituximab in patients with relapsed/refractory aggressive and indolent B-
30 21	543		cell lymphoma Leukemia & lymphoma, Oct 2022;63(10):2503-2506
37	544	38	Allan IN Helbig D Mulvey F et al Zanubrutinib and Venetoclay As Initial
33	545	50.	Therapy for CLL/SLL with Objuturuman Triplet Consolidation in Patients
34	546		with Minimal Basidual Disaasa Basitivity (BryVanG) Pland 2022/11/02/
35	540		with Minimar Residual Disease Positivity (Bruvend). <i>Biooa</i> . 2025/11/02/
36	547	20	2023;142:3283.
38	548	39.	Geng H, Jia S, Zhang Y, et al. Efficacy and safety of zanubrutinib plus R-CHOP
39	549		in treatment of non-GCB DLBCL with extranodal involvement. Frontiers in
40	550		immunology. 2023;14:1219167.
41	551		
42	551		
44	550		
45	332		
46			
47	553		
48 49	554		
50			
51			
52			
53 54			
54 55			
56			
57			
58			
59 60			
00			

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Figure titles and legends

- Figure 1. Forest plot of the AEs for zanubrutinib at the System Organ Class Level. SOC,
- system organ class; CI, confidence interval.
- Figure 2. Forest plot of the top 25 AE risk signals for zanubrutinib. PT, preferred term;
- ROR, reported odds ratio; CI, confidence interval.
- Figure 3. Time to onset of zanubrutinib-related AEs.
- Figure 4. Volcano plots of the difference in PT signals between zanubrutinib+rituximab
- and Zanubrutinib alone. ROR, reported odds ratio.

1	
2	
3	
4	
5	
5	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
17	
10	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
<u>م</u>	
11	
40	
4∠ ∡⊃	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
55	
54	
55	
56	
57	
58	
59	

566	Table titles and legends
-----	--------------------------

Tuble titles and leg	chus
Table 1	Characteristics of reports associated with Zanubrutinih

	Zanubrutinib	Zanubrutinib+ Rituximab			
	n (%)	n (%)			
Number of reports	848	166			
Number of adverse events	2826	603			
Sex					
Female	8 (0.9%)	30 (18.1%)			
Male	19 (2.2%)	49 (29.5%)			
Missing	821 (96.8%)	87 (52.4%)			
Age(years)					
≥86	3 (0.4%)	1 (0.6%)			
65~85	14 (1.7%)	27 (16.3%)			
18~64	4 (0.5%)	35 (21.1%)			
Missing	827 (97.5%)	103 (62.0%)			
Outcomes					
Death	64 (7.5%)	8(4.8%)			
Life-threatening	15 (1.8%)	3(1.8%)			
Hospitalization	218 (25.7%)	25(15.1%)			
Disability	7 (0.8%)	2(1.2%)			
Congenital Anomaly	1 (0.1%)	0			
Required intervention	2 (0.2%)	0			
Other Serious	176 (20.8%)	96(57.8%)			
Missing	365 (43.0%)	32(19.3%)			
Reporter's Occupation					
Consumer	342 (40.3%)	8 (4.8%)			
Health professional	122 (14.4%)	64 (38.6%)			
Physician	280 (33.0%)	84 (50.6%)			
Pharmacist	95 (11.2%)	9 (5.4%)			
Missing	9 (1.1%)	1 (0.6%)			
Reporter Countries	Reporter Countries				
USA	523 (61.7%)	15 (9.0%)			
China	141 (16.6%)	103 (62.0%)			
Australia	52 (6.1%)	36 (21.7%)			
Canada	29 (3.4%)	1 (0.6%)			
Others	103 (12.2%)	11(6.7%)			

568 569

570

		BMJ Open	stober : Ses relg	Page 26 of 33
SOC	Ν		2022 atec	ROR(95% CI)
1 Injury, poisoning and procedural complications	471		1. D to	1.46(1.32-1.61)
² General disorders and administration site conditions	390	HEH I	tex	0.74(0.67-0.83)
Investigations	244		t ar	1.51(1.32-1.72)
5 Infections and infestations	240		nd d	1.57(1.38-1.79)
6 Skin and subcutaneous tissue disorders	238		ata d fr	1.61(1.41-1.84)
7 Gastrointestinal disorders	222		<u>n</u> i BE	1.01(0.88-1.16)
8 Nervous system disorders	143		ning S)	0.68(0.57-0.8)
9 Respiratory, thoracic and mediastinal disorders	130		9, A	1.02(0.86-1.22)
10 11 Blood and lymphatic system disorders	129			2.78(2.33-3.32)
12 Musculoskeletal and connective tissue disorders	128		aini ope	0.87(0.73-1.04)
13 Cardiac disorders	72		ng,	1.3(1.03-1.65)
14 Vascular disorders	60	· · · · · · · · · · · · · · · · · · ·	ang <u>mi</u>	1.15(0.89-1.48)
Renal and urinary disorders	53	·	si on	0.97(0.74-1.28)
10 17 Neoplasms benign, malignant and unspecified (incl cysts a	and polyps) 51	⊢ ∎	mila	0.41(0.31-0.54)
18 Psychiatric disorders	49		ar te	0.3(0.23-0.4)
19 Surgical and medical procedures	49		ichi	1.22(0.92-1.62)
20 Metabolism and nutrition disorders	47	·	7, 2	0.87(0.65-1.16)
21 Eye disorders	34		2022 Dgie	0.63(0.45-0.88)
22 23 Hepatobiliary disorders	20	·	is at	0.88(0.57-1.36)
24 Ear and labyrinth disorders	15		Ag	1.3(0.78-2.16)
25 Immune system disorders	13	— — ——————————————————————————————————	enc	0.4(0.23-0.69)
26 Product issues	10 🛏	<u> </u>	Ö	0.19(0.1-0.36)
27 Reproductive system and breast disorders	9			0.51(0.26-0.98)
28 Social circumstances	4 ⊢	······	ogr	0.3(0.11-0.79)
30 Congenital, familial and genetic disorders	3 🛏		aph	0.39(0.13-1.21)
31 Endocrine disorders	2		Ĭġ	0.27(0.07-1.09)
32	0	1 2		4
33	For peer review	only - http://bmjopen.bmj.com/site/about/guide	elines.xhtml	
34				

Page 27 of 33	PT		BMJ Open	ROR(95% CI)	Zanubrutinib(N)	Others(N)
1	Haemorrhage subcutaneous	_ -		190.8(128-284.5)	25	867
3	Penile haemorrhage	•	_	112.6(35.9-352.6)	3	175
5	Petechiae	~		40.7(24.8-66.5)	16	2596
7 8	Blood blister	~		40.3(16.7-97.2)	5	815
9 10	Meningitis cryptococcal	~		40.1(12.9-124	3	491
11 12	Ecchymosis	• -		34.6(17.3-69.4)	8	1521
13 14 15	Haemorrhagic diathesis	•		29.7(11.1-79.2)	4	886
16 17	Pneumonia fungal	• -		23.7(10.6-53 6	6	1661
18 19	Hepatitis B	•		21.8(8.2-58.3	4	1203
20 21	Myelosuppression	•		19.7(14.4-27.1) 19.7	39	13143
22 23	Contusion	•		17.2(13.5-21.9) t 0	68	26538
24 25	White blood cell count increased	•		ជាភ្លេង 16.1(10.6-24.ទី) ទំព័ន្ធ	22	9042
26 27	Hypernatraemia	←		da ur Ga 15(4.8-46.6)ta 15(4.8-46.6)ta	3	1314
28 29 20	Increased tendency to bruise	◆ -		13.7(5.7-33.13) 0.000	5	2392
31 32	Hepatitis B reactivation	◆ -		13.1(4.2-40.7	3	1504
33 34	Blood urine present	◆		12.7(6.6-24.4	9	4664
35 36	Tumour lysis syndrome	◆		11.1(4.6-26.8)	5	2949
37 38	Haemolysis	←		11.1(3.6-34.4	3	1779
39 40	Purpura	←		10(3.2-31.1)	3	1964
41 42	Atrioventricular block	←		9.9(3.2-30.8)	3	1988
43 44 45	Subdural haematoma	◆		9.7(4-23.4)	5	3381
45 46 47	Eye haemorrhage	◆		9.7(4-23.2)	5	3400
48 49	Haemoglobin abnormal	←		9.5(3.1-29.6)	3	2066
50 51	Intestinal perforation	◆		9.5(3.6-25.4)	4	2764
52 53	Pericardial effusion	•		7.4(3.5-15.5)	7	6234
54 55	Fc	(peer review only - http:/)jbn 1 100 200 300	njopen.bmj.com/site/abo 400 500 600	out/guidelines.xhtml		





Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Supplementary

Table S1. Formulas and signal detection criteria for ROR.

Formula	Signal standard
ROR = (ad/bc)	 lower limit of ROR 95%CI > 1;
	· a ≥3
ROR 95%CI = $e^{\ln (ROR) \pm 1.96 \sqrt{(\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d})}}$	

a: number of specific adverse events to the target drug; b: number of other adverse events to the target drug; c: number of specific adverse events to background drugs; d: number of other adverse events to the background drug;

ROR: reporting odds ratio, CI: confidence interval

soc	РТ	n	ROR(95%CI)
Blood and lymphatic system	Myelosuppression	39	19.7(14.4-27.1)
disorders	Febrile neutropenia	14	4.4(2.6-7.4)
	Neutropenia	13	1.8(1-3)
	Increased tendency to bruise	5	13.7(5.7-33.1)
	Haemorrhagic diathesis	4	29.7(11.1-79.2)
	Cytopenia	4	5.2(1.9-13.8)
	Haemolysis*	3	11.1(3.6-34.4)
Cardiac disorders	Atrial fibrillation	21	4.9(3.2-7.6)
	Pericardial effusion*	7	7.4(3.5-15.5)
	Atrioventricular block	3	9.9(3.2-30.8)
	Ventricular tachycardia	3	5(1.6-15.5)
Ear and labyrinth disorders	Ear discomfort*	3	6.9(2.2-21.5)
Eye disorders	Eye haemorrhage	5	9.7(4-23.2)
Gastrointestinal disorders	Dysphagia	14	4(2.4-6.8)
	Dyspepsia*	8	2.1(1-4.2)
	Intestinal perforation*	4	9.5(3.6-25.4)
	Faeces discoloured	3	3.8(1.2-11.7)
	Haematemesis	3	3.3(1.1-10.2)
	Tooth disorder*	3	3.2(1-10.1)
General disorders and	Fatigue	50	1.4(1-1.8)
administration site conditions	Asthenia	30	2(1.4-2.9)
	Peripheral swelling	18	2(1.3-3.2)
	Oedema peripheral	12	3.4(1.9-5.9)
	Oedema	5	2.6(1.1-6.3)
	Mass*	3	4.9(1.6-15.2)
Hepatobiliary disorders	Hepatic function abnormal	5	3.2(1.3-7.6)
Infections and infestations	Urinary tract infection	19	2.4(1.6-3.8)
	Infection	15	2.2(1.3-3.6)
	Cellulitis	10	4.8(2.6-8.9)
	Sepsis	9	2(1-3.8)
	Pneumonia fungal	6	23.7(10.6-53)
	Hepatitis B	4	21.8(8.2-58.3)
	Meningitis cryptococcal	3	40.1(12.9-124.9)
	Hepatitis b reactivation	3	13.1(4.2-40.7)
	Pneumocystis jirovecii pneumonia	3	5.5(1.8-17.2)
	Skin infection	3	5.4(1.7-16.8)
Injury, poisoning and	Contusion	68	17.2(13.5-21.9)
procedural complications	Subdural haematoma	5	9.7(4-23.4)
Investigations	Platelet count decreased	29	5.7(4-8.3)
	White blood cell count decreased	24	4.4(2.9-6.6)

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	White blood cell count increased	22	16.1(10.6-24.5)
	Haemoglobin decreased	14	3.4(2-5.8)
	Blood urine present	9	12.7(6.6-24.4)
	Blood creatinine increased	8	3(1.5-6.1)
	Red blood cell count decreased	6	4.4(2-9.7)
	Haemoglobin abnormal	3	9.5(3.1-29.6)
	Blood iron decreased*	3	4.7(1.5-14.7)
Metabolism and nutrition	Tumour lysis syndrome	5	11.1(4.6-26.8)
disorders	Hypernatraemia*	3	15(4.8-46.6)
	Increased appetite*	3	4.7(1.5-14.7)
Musculoskeletal and	Musculoskeletal pain	4	2.8(1.1-7.6)
connective tissue disorders	Haemarthrosis	3	4.7(1.5-14.7)
Nervous system disorders	Hypersomnia*	4	3.3(1.2-8.8)
	Haemorrhage intracranial	3	6.3(2-19.6)
Renal and urinary disorders	Haematuria	8	5.9(3-11.9)
	Dysuria	5	3.5(1.4-8.3)
Reproductive system and breast disorders	Penile haemorrhage	3	112.6(35.9-352.6)
Respiratory, thoracic and	Pleural effusion	14	6.2(3.7-10.5)
mediastinal disorders	Epistaxis	8	2.7(1.3-5.4)
	Sinus disorder	4	4.4(1.6-11.7)
Skin and subcutaneous tissue	Rash	48	2.4(1.8-3.2)
disorders	Haemorrhage subcutaneous	25	190.8(128-284.5)
	Petechiae	16	40.7(24.8-66.5)
	Skin discolouration*	10	5.1(2.7-9.5)
	Rash macular	9	5.8(3-11.2)
	Ecchymosis	8	34.6(17.3-69.4)
	Night sweats	6	4.5(2-10)
	Rash pruritic	6	2.8(1.2-6.2)
	Blood blister	5	40.3(16.7-97.2)
	Skin lesion	4	3.1(1.2-8.4)
	Purpura	3	10(3.2-31.1)
	Hair texture abnormal*	3	4.9(1.6-15.2)
	Skin haemorrhage	3	4.6(1.5-14.3)
Vascular disorders	Haemorrhage	18	4.4(2.7-6.9)
* unexpected adverse event			

SOC, system organ class; PT, preferred term; ROR, reporting odds ratio; CI, confidence interval.



Figure S1. The flow diagram of screening zanubrutinib-related AEs from the FAERS database. DEMO, demographic and administrative information; DRUG, drug information; REAC, adverse event information; PT, preferred term.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



Figure S2. Forest plot of the important medical event signals for zanubrutinib. ROR, reported odds ratio; CI, confidence interval.

.Va.
BMJ Open

Real-world Safety Profile of Zanubrutinib: a Disproportionality Analysis based on the FAERS Database

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-084991.R1
Article Type:	Original research
Date Submitted by the Author:	05-Sep-2024
Complete List of Authors:	Wang, Jiangfeng; Ipharmacare Ltd, Department of Pharmaceutical Services Zheng, Xiaochun; Zhejiang Provincial People's Hospital, Pharmacy Lin, Jingyang; Hangzhou Medical College, Department of Cardiovascular Medicine Huang, Jinlong; Hangzhou Normal University; Hangzhou Medical College, Department of Pharmacy Zhang, Miaomiao; Hangzhou Normal University; Hangzhou Medical College, Department of Pharmacy Huang, Ping; Hangzhou Medical College, Department of Pharmacy Yang, Xiuli; Hangzhou Medical College, Department of Pharmacy
Primary Subject Heading :	Medical management
Secondary Subject Heading:	Medical management, Health services research
Keywords:	Adverse events < THERAPEUTICS, CLINICAL PHARMACOLOGY, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



1 2		
3	1	Real-we
5 6 7	2	
7 8	-	
9 10	5	
11 12	4	Jiangfeng
13 14	5	BSc, ^{4,2} N
15 16		
17	6	
19		
20 21	7	
22 23	8	1Departn
24 25	0	Departi
26 27	9	China
28 29	10	20
30 31	10	² Center
32	11	Provincia
33 34	12	Hanozho
35 36	12	1141192110
37 38	13	³ Heart C
39 40	14	Hermitel
41 42	14	Hospitai
43 44	15	Zhejiang
45		10.1
40	16	⁴ School o
48 49	17 18	
50 51	18	
52	20	
53	21	
54 55	22	
56	23	
57	24	
58 59	25	
60	26	

1	Real-world Safety Profile of Zanubrutinib: a Disproportionality Analysis based
2	on the FAERS Database
3	
4	Jiangfeng Wang, MM, ¹ Xiaochun Zheng, MM, ² Jingyang Lin, MM, ³ Jinlong Huang,
5	BSc, ^{4,2} Miaomiao Zhang, BSc, ^{4,2} Ping Huang, MD, ^{2*} Xiuli Yang, MM, ^{2*}
6	
7	
8	¹ Department of Pharmaceutical Services, Ipharmacare Ltd., Hangzhou, Zhejiang,
9	China
10	² Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang
11	Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College,
12	Hangzhou, Zhejiang, China;
13	³ Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's
14	Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou,
15	Zhejiang, China 310014;
16	⁴ School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China;
17	
18	
19	
20	
21	
22 73	
23 24	
25	

BMJ Open

Corresponding Author: Ping Huang, MD, Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, 158 Shangtang Rd, Gongsu District, Hangzhou, Zhejiang310014, China (Email: huangpwly@sina.com); Xiuli Yang, MM, Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 158 Shangtang Rd, Gongsu District, Hangzhou, Zhejiang310014, China (Email: xiuli8245@163.com) Abstract **Objective:** Zanubrutinib is a second-generation BTK inhibitor that has been approved for the treatment of several B-cell malignancies. The aim of this study was to evaluate adverse events (AEs) associated with zanubrutinib based on real-world data. Design: A disproportionality analysis was performed to identify the potential zanubrutinib-related AEs. Setting: The Food and Drug Administration Adverse Event Reporting System (FAERS) database from the fourth quarter of 2019 to the third quarter of 2023. Main outcome measures: The results of the disproportionality analyses were

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

presented as reported odds ratios (ROR). When the lower limit of the 95% confidence interval (CI) for the ROR is greater than 1 and the number of AE reports is \geq 3, it indicates that the preferred term (PT) may be a positive AE signal. **Results:** A total of 846 AE reports with zanubrutinib as the primary suspect (PS) drug were obtained, with 2,826 AEs. A total of 74 positive PT signals were detected across 18 system organ classes (SOCs). The most significant signal for SOC was "Blood and lymphatic system disorders" (ROR = 2.8, 95% CI 2.3-3.3), while the most significant signal for PT was "Haemorrhage subcutaneous" (ROR = 190.8, 95% CI 128.0-284.5). Thirteen unexpected off-label AEs were also observed, such as abnormal hair texture, skin discolouration, hypernatraemia, pericardial effusion, and hypersomnia. The median time to onset of AEs associated with zanubrutinib was 51 days (interquartile range 13-192 days) and was consistent with the early failure model. In comparison to zanubrutinib monotherapy, the combination of zanubrutinib and rituximab therapy was linked to a higher risk of specific AEs, including myelosuppression, pneumonia, leukopenia, thrombocytopenia, abdominal pain, anaemia, pancytopenia, and respiratory failure. Furthermore, the combination of zanubrutinib and chemotherapy increased the risk of several severe AEs, such as cardiac arrest, elevated blood lactate dehydrogenase levels, and pancytopenia.

 Conclusions: The results of the analysis provided valuable insights into the safety
profile of zanubrutinib-treated patients, which was helpful for clinical monitoring and
identifying potential AEs related to zanubrutinib.

BMJ Open

2	
3	
4	
5	
5 6	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20	
ו∡ רב	
22	
23	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
34	
35	
36	
37	
20	
20	
39	
40	
41	
42	
43	
44	
45	
46	
17	
4/	
48	
49	
50	
51	
52	
53	
54	
55	
55	
50	
5/	
58	
59	
60	

73	Streng	ths and limitations of this study
74	• Th	e present study employs a disproportionality analysis to identify potential
75	ad	verse events (AEs) associated with Zanubrutinib, utilizing the Food and Drug
76	Ac	Iministration Adverse Event Reporting System (FAERS).
77	• Re	ported odds ratios (RORs) and their corresponding 95% confidence intervals

- 78 (CIs) were employed to identify the potential signals.
- The FAERS database is a self-reporting system that may have some limitations, 79 such as incomplete information and awareness bias. 80
 - 81 The disproportionality analysis indicated a statistical correlation, but did not 82 establish a definitive causal relationship between the target drug and the specific íe. R 83 AEs.
 - 84

85 Induction 1.

Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that is a member of 86 87 the Tec (tyrosine kinase expressed in hepatocellular carcinoma) kinase family.^{1,2} BTK 88 is mainly expressed in B lymphocytes, myeloid cells, and platelets.³ BTK is a vital 89 signalling molecule in B-cell receptor (BCR) pathway and plays a crucial role in B-cell 90 differentiation, proliferation, and survival.² The treatment of B-cell malignancies has 91 been greatly improved by the development of the inhibition of Bruton's tyrosine kinase. 92 Since the approval of the first BTK inhibitor, ibrutinib, by the US Food and Drug 93 Administration (FDA) in 2013, a variety of BTK inhibitors have been used clinically 94 to treat patients with B-cell malignancies over the past decade and have demonstrated

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

95 significant efficacy.⁴⁻⁹

Zanubrutinib is a selective second-generation oral BTK inhibitor that covalently and irreversibly binds to Cys-481 in the BTK ATP binding site.¹⁰ By optimizing the molecular structure, zanubrutinib improves BTK target selectivity and minimizes off-target binding, resulting in more precise and sustained BTK inhibition.^{10,11} Zanubrutinib was first approved by the FDA in November 2019 to treat patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). ¹⁰ The approval was based on the results of two studies: phase 1/2 study BGB-3111-AU-003 (NCT02343120) and phase 2 study BGB-3111-206 (NCT0320697). The trial NCT02343120 recruited 32 patients who had previously received treatment for MCL. The study achieved an overall response rate (ORR) of 84%, with a complete response rate (CRR) of 29.7%.¹² In the phase II trial, 72 of 86 patients (84%) achieved an objective response (OR), with 59 (68.6%) of them achieving a complete response (CR). ¹³ The median duration of response (DOR) and progression-free survival (PFS) were 19.5 and 22.1 months, respectively. Zanubrutinib was approved by the FDA in August 2021 for the treatment of Waldenström's macroglobulinemia (WM) and in September 2021 for marginal zone lymphoma (MZL).¹¹ In January 2023, zanubrutinib was granted FDA approval for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) based on the results of the ALPINE and SEQUOIA trials. The ALPINE study, an open-label, multicentre, randomized, phase III clinical trial evaluating the efficacy and safety of zanubrutinib versus ibrutinib in 652 patients with R/R CLL/SLL, showed that zanubrutinib was superior to ibrutinib in terms of ORR and PFS.¹⁴ The SEQUOIA

study, which randomized patients with previously untreated CLL/SLL to zanubrutinib
or bendamustine plus rituximab, showed a significant improvement in progression-free
survival with zanubrutinib compared to bendamustine-rituximab.¹⁵

Although BTK inhibitors have shown impressive efficacy and activity, they still require careful attention to safety and monitoring for some unique toxic reactions.¹⁶ Pooled data from six zanubrutinib monotherapy trials involving 779 patients showed that 98% of patients experienced at least one adverse event (AE).¹⁷ The most common nonhematologic AEs were upper respiratory tract infection, rash, bruising, musculoskeletal pain, diarrhoea, cough and pneumonia, urinary tract infection, fatigue, hematuria, constipation, headache, pyrexia, hypertension, and nausea. However, clinical trials are conducted under strict limitations, and AEs of zanubrutinib observed in clinical trials may not fully reflect all AEs observed in clinical practice. Therefore, a comprehensive assessment of the post-marketing safety of zanubrutinib based on real-world data is needed.

131 The FDA Adverse Event Reporting System (FAERS) is a free database of spontaneous 132 AE reports submitted by manufacturers, healthcare professionals, individual patients 133 and others. FAERS is widely used in signal mining studies of AEs, which can 134 effectively monitor and evaluate the post-marketing safety of drugs.¹⁸ In the present 135 study, we used data mining of FAERS to retrospectively identify and investigate the 136 signals of zanubrutinib-associated ADRs.

2. Methods

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

139 2.1. Patient and public involvement

140 Patients and the public were not involved in our study.

2.2. Data Sources and Cleaning

This disproportionality analysis was performed to analyze zanubrutinib-related AEs using data from the FAERS database. Data ranging from the fourth quarter of 2019 (when zanubrutinib was approved by the FDA) to the third quarter of 2023 were selected for analysis. FAERS data is composed of seven datasets: demographic and administrative information (DEMO), drug information (DRUG), adverse event information (REAC), drug therapy start dates and end dates (THER), indications for the reported drugs (INDI), patient outcomes information (OUCT), and reported sources (RPSR). PRIMARYID linked the same AE report across different datasets. Data units from different seasons were combined using R software. Prior to statistical analysis, we performed deduplication based on the following standards: if the PRIMARYIDs were identical, the most recent FDA DT was chosen, if both the PRIMARYIDs and FDA DTs were identical, the lower PRIMARYIDs were deleted.¹⁹

2.3. Adverse Event Identification and Mining

Various drug names including "zanubrutinib", "BGB 3111" and "Brukinsa" were used in the search for zanubrutinib. In the FAERS database, there are four codes for the role of drugs in reported AEs: Primary Suspect (PS), Secondary Suspect (SS), Concomitant (C), and Interacting (I). Only reports that document zanubrutinib as the role code of PS were selected for analysis to improve accuracy. AE reports in the FAERS database are coded using Preferred Terms (PTs) from the Medical Dictionary for Regulatory

Activities (MedDRA). For the present analysis, the PTs and System Organ Classes (SOC) were categorized according to MedDRA version 26.1. The European Union Drug Regulating Authorities Pharmacovigilance of Important Medical Events (IME) was utilized to evaluate serious adverse events. Additionally, clinical characteristics such as gender, age, outcomes of AEs, country of report, and reporter occupation were gathered.

A disproportionality signal occurs when the reported incidences of AEs for a targeted drug are higher than those in the background data. Reporting odds ratios (ROR) were used in our analysis to identify potential signals that may indicate an increased risk of drug-associated AEs for zanubrutinib. The ROR was calculated using a two-by-two contingency table that contrasted the reported event counts for the target medication with those of other background drugs.²⁰ The calculation formula of ROR is shown in Supplementary Table S1. The magnitude of the ROR value represents the strength of the association between the reported drug and specific AE. The signal of PT was considered positive if the lower limit of the 95% confidence interval (CI) for ROR was greater than 1 and the number of AE reports was ≥ 3.20 PTs related to the progression of disease, medication errors, and surgical operations were excluded.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2.4. Subgroup analysis

Subgroup analyses were conducted to investigate the correlation between zanubrutinib
and AEs within defined subgroups, classified according to indication and geographical
region. The currently approved indications for zanubrutinib included MCL, CLL/SLL,
WM, MZL, and follicular lymphoma (FL). Owing to the limited number of cases of

Page 10 of 40

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

MZL and FL in our dataset, the subgroup analysis by indication was primarily focused
on MCL, CLL/SLL, and WM. With regard to regional subgroups, distinct analyses
were performed for the United States and China, as these two countries constituted the
largest number of cases in our dataset.

187 2.5. Time-to-onset analysis

The time-to-onset of AEs was calculated by subtracting the zanubrutinib initiation date (START DT) from the AE onset date (EVENT DT). AE reports with incomplete dates, no dates, and incorrectly formatted dates were excluded. The time-to-onset was described using the Weibull shape parameter test and the proportion of events by time. The Weibull distribution is a continuous probability distribution that is described by a scale parameter (α) and a shape parameter (β). The time-to-onset analysis predicted the risk of AEs over time-based on the shape parameter. The predicted results were classified into three categories: early failure", "random failure", or "wear-out failure". If both the shape parameter and its 95% CI were less than 1, the risk of AE is estimated to decrease over time, which is referred to as early failure. If the shape parameter is equal to or close to 1 and its 95% CI encompasses 1, the risk of AE is considered not to change over time, which is referred to as "random failure". If both the shape parameter and its 95% CI were above 1, the risk of AE is predicted to increase gradually, which is referred to as "wear-out failure".²¹

2.6. Drug combination analysis

203 The safety of zanubrutinib in combination with other drugs was also investigated. First,204 the drugs used in combination were retrieved from all reports that included zanubrutinib

BMJ Open

(PS, SS, I, and C) and ranked according to the number of cases of combination. Preliminary results showed that the drug with the highest number of combinations with zanubrutinib was rituximab. Further disproportionality analyses were then performed on the drugs with the highest number of combination cases. In the disproportionality analyses for combination therapy, target drug cases were defined as zanubrutinib (PS) + rituximab (any role code) or rituximab (PS) + zanubrutinib (any role code), and background data were defined as zanubrutinib (PS) without rituximab. When the ROR signal was positive and p-value < 0.05 (chi-squared test), this indicated that the combination therapy was more likely to cause a specific AE than zanubrutinib monotherapy.²² The second most common drug combined with zanubrutinib was cyclophosphamide. Therefore, a further analysis was performed to explore the risk of AEs associated with the combination of zanubrutinib and chemotherapy.

R software version 4.3.2 was used for all data cleaning, mining, statistical analyses, andgraphs.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3. Result

3.1. Population Characteristics

A total of 7,575,864 AE reports were recorded in the FAERS database between October 222 2019 and September 2023 (Supplementary Figure S1). After removing duplicates, there 223 were 846 AE reports associated with zanubrutinib as the PS, documenting a total of 224 2,826 zanubrutinib-related AEs. Patient characteristics are summarized in Table 1. In 225 the included cases, hospitalization - initial or prolonged was the most common severe 226 outcome, accounting for 25.7% (218/848). AEs with zanubrutinib resulted in 64 deaths

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

(7.5%). Approximately 60% of the reports were submitted by healthcare professionals,
such as physicians (33.0%), pharmacists (11.2%), and other healthcare professionals
(14.4%). The majority of AEs were reported from the United States (61.7%), followed
by China (16.6%).

A total of 166 cases were reported in the FAERS for the combination of zanubrutinib
and rituximab, with either zanubrutinib or rituximab as the PS. The most frequent
severe outcome of adverse events remained the hospitalization - initial or prolonged.
The majority of the reports (62.0%) originated from China. Additionally, there were 78
reports associated with the combination of zanubrutinib and chemotherapy.

3.2. Signal of System Organ Classifications

AEs induced by zanubrutinib were found in 26 different organ systems (Figure 1). Among them, six significant SOCs were identified, including "Blood and lymphatic system disorders", "Skin and subcutaneous tissue disorders", "infections and infestations", "Investigations", "Injury, poisoning and procedural complications", and "Cardiac disorders".

3.3. Signal of preferred terms

A total of 74 positive PT signals belonging to 18 SOCs were detected in our analysis. Several positive signals that may be associated with lymphoma complications, such as "blood lactate dehydrogenase increased", "splenomegaly", "blood immunoglobulin M increased", and "lymphadenopathy" were not taken into account. The top 25 AEs with the highest ROR for zanubrutinib are displayed in Figure 2, and the full list of positive PT signals based on the SOCs is listed in Supplementary Table S2. The

BMJ Open

strongest AE signal was the PT of "Haemorrhage subcutaneous" (ROR = 190.8, 95%
CI 128.0-284.5), followed by "Penile haemorrhage" (ROR = 112.6, 95% CI 35.9-352.6).
Most of the positive signals were reported in previous clinical studies or listed on the
label for zanubrutinib. Nevertheless, thirteen positive signals, such as skin
discolouration, abnormal hair texture, hypernatremia, pericardial effusion, and
hypersomnia, were not mentioned on the label.

In addition, 20 of the 74 positive PT signals were considered serious AEs according to
the IME list (Supplementary Figure S2). The largest number of cases occurred in
myelosuppression, with 39 reported cases.

3.4.

3.4. Results for Subgroup Analysis

The results of the indication-based subgroup disproportionate analysis are presented in Supplementary Table S3. Across the MCL, CLL/SLL, and WM subgroups, the ROR for the AE of "haemorrhage subcutaneous" was found to be consistently the highest, with values of 32.2 (95% CI 9.4-110.3), 41.3 (95% CI 19.0-89.6), and 46.6 (95% CI 12.3-175.9), respectively. The most frequently reported AE in the MCL subgroup was dyspnea, with 11 cases, in the CLL/SLL subgroup was a contusion, with 21 cases, and in the WM subgroup was rash, with 18 cases. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

In the subgroup analysis of the United States population, a total of 68 Preferred Terms
(PTs) exhibited positive signals (Supplementary Table S4). Notably, "Haemorrhage
subcutaneous" demonstrated the strongest signal with an ROR of 601.7 (95% CI 369.4980.3). This was followed by "Penile haemorrhage" (ROR = 176.1, 95% CI 55.7-556.1)

270 and "Petechiae" (ROR = 87.7, 95% CI 53.4-143.9).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

In the Chinese population, the highest signal PT was "haemolysis" (ROR=44.8, 95%) CI 13.8-145.0), followed by "hepatitis B" (ROR=40.0, 95% CI 12.4-129.1) and "tumour lysis syndrome" (ROR=31.3, 95% CI 9.8-100.3).

3.5. Results for the time-to-onset analysis

After excluding reports with incomplete dates, a total of 223 reports were included in the time-to-onset analysis, with a median onset time of 51 days (interquartile range [IQR] 13-192). Out of the 223 reports, 91 (40.8%) occurred during the first month of zanubrutinib treatment, and a total of 164 (73.5%) occurred within six months of the initial dose (Figure 3). A scale parameter of 123.7 (95% CI 95.0-152.4) and a shape parameter of 0.60 (95% CI 0.54-0.66) were obtained when fitting the time-to-onset to the Weibull distribution. It indicated that the risk of AEs associated with zanubrutinib should be referred to as 'early failure', and that the likelihood of experiencing AEs decreases over time.

3.6. Results for the combination analysis

The five most commonly combined drugs with zanubrutinib in all reports from Q4 2019 through Q3 2023 in the FAERS database were rituximab (n = 373), cyclophosphamide (n = 231), prednisone (n = 216), obinutuzumab (n = 205), and vincristine (n = 114). A disproportionality analysis was conducted to investigate the impact of co-administering rituximab on the safety profile of zanubrutinib. The results showed that 10 AEs (Figure 4), such as myelosuppression, pneumonia, leukopenia, and platelet count decreased, may be more likely to occur in patients treated with rituximab + zanubrutinib than in patients treated with zanubrutinib alone. Furthermore, the analysis of zanubrutinib Page 15 of 40

BMJ Open

293 combined with chemotherapy revealed that nine AEs, such as cardiac arrest, increased 294 blood lactate dehydrogenase levels, and pancytopenia, were at a higher risk of 295 occurrence in the patient group receiving chemotherapy plus zanubrutinib than in those 296 on zanubrutinib monotherapy.

297 4. Discussion

BTK inhibitors have demonstrated superior clinical efficacy and tolerability in patients with B-cell malignancies in comparison to standard chemotherapy and immunotherapy regimens. ²³ The AEs related to BTK inhibitors were mostly classified as grade 1-2, with a low frequency of grade \geq 3 AEs.²⁴ The rate of treatment termination due to AEs was relatively low. The first-generation BTK inhibitor ibrutinib displayed significant off-target effects. It inhibited other kinases non-specifically and bound to other signalling channel proteins, leading to a range of AEs. In contrast, zanubrutinib was a next-generation BTK inhibitor that had improved specificity and off-target effects, resulting in a lower incidence of treatment-related AEs.^{8,9} Nonetheless, patients treated with zanubrutinib may experience unique AEs that require close monitoring to ensure optimal efficacy.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

A comprehensive disproportionality analysis of the safety profile of zanubrutinib was conducted based on post-marketing data from the FAERS database. In the almost four years since zanubrutinib was marketed, the FAERS database has documented 846 AE reports where zanubrutinib was the primary suspect. A total of 74 positive PT signals were identified, which were involved in 18 of the SOCs.

314 The disproportionality analysis revealed that the AEs with the most significant signal

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

> at the SOC levels were related to 'blood and lymphatic system disorders'. Hematologic toxicity, including neutropenia, thrombocytopenia, and anaemia, was one of the most common AEs associated with zanubrutinib. Neutropenia was one of the few AEs that occurred more frequently with zanubrutinib than with ibrutinib (29% vs. 13%; hazard ratio, 2.18; 95% CI, 1.15 to 4.12).9 The various complex mechanisms of immune dysregulation resulting from B lymphocytoma may contribute to the hematologic toxicity.²³ Severe hematologic toxicity may lead to dose adjustment or discontinuation of zanubrutinib therapy.^{8,9} The most common cause of zanubrutinib dose reductions is neutropenia.¹⁷ Jiang et al.²⁵ developed an XGBoost model to predict the severe haematological toxicity of BTK inhibitors. The XGBoost model was constructed based on ten parameters: leukocytes, neutrophils, erythrocytes, platelets, fibrinogen, total albumin, aspartate aminotransferase, lactate dehydrogenase, gender, and the type of BTK inhibitor. Among them, lactate dehydrogenase, neutrophils, BTK inhibitor (ibrutinib), and gender (female) were positively correlated with the outcome, while other factors were negatively correlated with the outcome. The XGBoost model is available online for clinical use.

331 Of the 74 positive PT signals we obtained, up to 18 were associated with haemorrhages, 332 such as eye haemorrhage, haematemesis, subdural hematoma, haemarthrosis, 333 haemorrhage intracr, haematuriaanial, penile haemorrhage, ecchymosis, and skin 334 haemorrhage. Bleeding was a frequently observed AE in patients treated with 335 zanubrutinib, and the majority of these AEs were mild (grade ≤ 2).^{8,17} Clinical studies 336 have shown that bleeding events of any grade occurred in 4.4%-66.0% of patients

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

treated with zanubrutinib, with major bleeding occurring in 0.3%-3.5%. ^{8,9,17,26} Bleeding was more likely to occur in patients \geq 75 years. ¹⁷ Patients who suffered a bleeding event of \geq grade 3 needed to discontinue zanubrutinib permanently unless the risk of rebleeding was deemed acceptable.²³ Studies have shown an increased risk of bleeding when BTK inhibitors are combined with anticoagulants or antiplatelet agents.²³

Studies on the pathophysiology of zanubrutinib-associated bleeding are limited. Currently, the mechanisms of haemorrhage associated with BTK inhibitors are mainly explored based on ibrutinib.^{3,27} It has been suggested that the risk of bleeding associated with BTK inhibitors may be due to both on- and off-target effects. BTK and TEC interfered with collagen-induced platelet activation by regulating the platelet transmembrane receptors, including the platelet glycoprotein VI (GPVI) and the C-type lectin-like receptor 2 (CLEC-2). GPVI is the main signalling receptor for collagen. The binding of collagen to GPVI triggers the platelet activation cascade.²⁸ CLEC-2 activates signal transduction via tyrosine phosphorylation of a single YXXL motif in its cytoplasmic tail, which triggers the platelet activation cascade.²⁹ BTK inhibitors irreversibly inhibit the BTK and TEC leading to the inhibition of GPVI- and CLEC-2mediated platelet activation.^{3,27} In addition to GPVI and CLEC-2 signalling, inhibition of the GPIb and aIIb_β3-integrin pathways may also contribute to bleeding caused by BTK inhibitors.^{3,16}

357 Patients treated with zanubrutinib were at high risk of infection due to358 immunosuppression. The infectious event with the most cases reported in the FAERS

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

359	database was urinary tract infection ($n = 19$; ROR 2.4; 95% CI 1.6 to 3.8). Opportunistic
360	infections, including fungal pneumonia (ROR=23.7, 95% CI 10.6-53.0), cryptococcal
361	meningitis (ROR=40.1, 95% CI 12.9-124.9), and pneumocystis carinii pneumonia
362	(ROR=15.5, 95% CI 1.8-17.2), were detected. The pooled safety analysis revealed that
363	infections had the highest incidence of AEs, with a 76% occurrence rate. ¹⁷ Additionally,
364	serious infections were reported in 27% of cases. The ALPINE trial showed that
365	infectious events were the most common AEs leading to discontinuation.8 The
366	mechanism of increased susceptibility to infection is complex, primarily involving the
367	effect of BTK inhibitors on the immune system. ²⁶ BTK played a crucial role in detecting
368	a broad spectrum of microbes via various Toll-like receptors. ³⁰ BTK inhibitors may
369	interfere with the sensing of pathogens. In addition, neutrophils are a crucial component
370	of the human immune system, serving as a key defender against pathogenic pathogens.
371	However, neutropenia is a common AE experienced by patients receiving zanubrutinib.
372	Unexpected and significant PT signals such as abnormal hair texture, skin
373	discolouration, hypernatremia, pericardial effusion, hypersomnia, intestinal perforation,
374	and blood iron decrease were detected in our analysis. All of the unexpected and novel
375	AEs need to be further confirmed in future studies and require vigilance in clinical
376	practice. Hair changes were thought to be one of the skin toxicities of ibrutinib, but
377	have not been reported in zanubrutinib-treated patients. A meta-analysis of 32 clinical
378	trials evaluated the dermatologic toxicity of ibrutinib. ³¹ Among the 32 clinical trials
379	included, two of the phase II clinical studies for the treatment of CLL/SLL reported hair
380	changes associated with ibrutinib (7.9%; 95% CI, 0.0-21.3%). A pharmacovigilance

Page 19 of 40

BMJ Open

381	analysis of ibrutinib and acalabrutinib using the FAERS database identified 84 cases of
382	ibrutinib-associated hair changes by December 2021 (ROR = 108.7, 95% CL 85.0-
383	139.1). ³² However, no positive signal was found for acalabrutinib. The proteins in the
384	keratinocytes of the hair contained an abundance of sulfur-containing amino acids that
385	formed disulfide bonds, which were important for the tensile strength and structural
386	integrity of the hair. ³³ The covalent binding of the BTK inhibitors to cysteine residues
387	in the BTK active site disrupted the disulfide bond between cysteine residues, which
388	may lead to hair changes. ³⁴ Skin discolouration, another unexpected dermatologic
389	toxicity that we detected, manifested primarily as abnormal skin pigmentation.
390	However, it was not detected in either ibrutinib or acalabrutinib. ^{31,32,34}
391	Our analysis revealed that the median time to onset of all AEs associated with
392	zanubrutinib was 51 days (IQR 13-192), with 73.5% of cases occurring within 6 months
393	of exposure to the drug. This onset time appears to be shorter than that of most AEs
394	reported in clinical studies. Clinical studies have shown that bleeding events, infectious
395	events, neutropenia, thrombocytopenia, anemia, and atrial fibrillation had a median
396	time to onset of 52 days (IQR 15-167), 89 days (IQR 29-199), 86 days (IQR 45-339),
397	84 days (IQR 28-343), 102 days (IQR 64-109), and 183 days (IQR 36-622),
398	respectively. ^{17,35}
399	As the combination regimens of zanubrutinib are gaining clinical interest, we conducted
400	a further search in the FAERS database for AEs associated with these combinations. ³⁶⁻

³⁹ According to our analysis, rituximab was the most frequently used agent in

combination with zanubrutinib, with a total of 373 reports. Out of these cases, 166 were

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

> identified as the PS for either zanubrutinib or rituximab. AEs that occur at higher risk in patients treated with zanubrutinib plus rituximab include myelosuppression, pneumonia, leukopenia, decreased platelet count, abdominal pain, anaemia, pancytopenia, respiratory failure, pneumonitis, and elevated blood lactate dehydrogenase. This is similar to the results of a phase II clinical study, which demonstrated that the combination of zanubrutinib and rituximab resulted in AEs with an incidence of $\geq 10\%$, including leukopenia, neutropenia, anaemia, upper respiratory tract infection, elevated liver enzymes, hematuria, pneumonitis, decreased platelet count, and purpura.³⁷ In the analysis of Zanubrutinib combined with chemotherapy, the highest risk was identified for cardiac toxicity, specifically the risk of cardiac arrest. This may be related to the significant cardiotoxicity of certain chemotherapeutic agents used in combination, such as cyclophosphamide, epirubicin, and pirarubicin. Our study existed several limitations that were inherent to data mining research with the FAERS database. First of all, The FAERS is a self-reporting database that inevitably contains omissions, incomplete information, arbitrary reporting, misreporting, and misinterpreted relationships, which can lead to potentially biased results in

the FAERS database. First of all, The FAERS is a self-reporting database that inevitably contains omissions, incomplete information, arbitrary reporting, misreporting, and misinterpreted relationships, which can lead to potentially biased results in disproportionality analyses. Secondly, the analysis did not account for potential confounding factors such as drug interactions and patient comorbidities, which could significantly influence the occurrence of AEs. Thirdly, the disproportionality analysis only revealed a statistical correlation, rather than a clear causal association between the target drug and the specific AEs. Therefore, further causal evaluation is required, which may include reviewing drug labels, literature reports, expert opinions, or conducting

well-designed clinical trials. However, signals identified through big data analytics
from post-marketing drug surveillance remain clinically significant in suggesting
potential drug risk.

428 5. Conclusion

The safety profile of zanubrutinib was analysed in the real world, revealing a strong association with haematological toxicity, bleeding, infection, and other AEs. These findings were consistent with the label and confirmed the reliability of this study. The analysis showed that zanubrutinib may be susceptible to AEs not listed on the label, such as abnormal hair texture, skin discolouration, hypernatraemia, pericardial effusion, and hypersomnia. The time-of-event analysis showed that zanubrutinib-related AEs were characterised by an early failure profile, indicating that the risk of zanubrutinib-related AEs was higher in the early stage of treatment, with a decreasing risk over time. Furthermore, our study elucidates the increased risk of several AEs associated with the combination of zanubrutinib and rituximab, including myelosuppression, pneumonia, leukopenia, thrombocytopenia, abdominal pain, anaemia, pancytopenia, and respiratory failure, compared to zanubrutinib monotherapy. Similarly, the combination of zanubrutinib with chemotherapy elevates the risk of nine AEs, such as cardiac arrest, elevated blood lactate dehydrogenase levels, and pancytopenia. Our study provides important evidence for the clinical safety of zanubrutinib.

445 Authors' contributions

446 Contributors JW and XY conceived and designed the study. XZ, JL, JH and MZ447 performed the data extraction and data analyses. JW drafted the manuscript. PH and

448 XY revised the manuscript. JW is the guarantor of the manuscript and accepts full
449 responsibility for the work. All authors have read and approved the version of the
450 manuscript submitted for publication.

Competing interests

452 All authors declare that they have no competing interests.

453 Funding

454 This study was supported by the Research Program for Medicine and Health Science
455 and Technology of Zhejiang Province (2022KY585, 2024KY761), Zhejiang
456 Pharmaceutical Association Foundation Project (2020zyy22), Zhejiang Medical
457 Doctors Association Foundation Project (YS2022-3-009). Role of the funder: The
458 funders had no role in the study, including collection, analysis, and interpretation of the
459 data, writing of the manuscript, and the decision to submit the manuscript for
460 publication.

Patient and public involvement

462 Patients and/or the public were not involved in the design, conduct, reporting, or463 dissemination plans of this research.

Ethics approval

465 Patient information in the FAERS database is anonymized. Therefore, ethical approval466 according to the Declaration of Helsinki is not required.

467 Data sharing statement

468 The datasets generated during and/or analysed during the current study are available469 from the corresponding author upon reasonable request.

471 Acknowledgements

472 Not applicable.

Reference

477	1.	Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer
478		journal. Nov/Dec 2019;25(6):386-393.
470	2	

- 479 2. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B
 480 cells and malignancies. *Molecular cancer*. Feb 19 2018;17(1):57.
- 481 3. von Hundelshausen P, Siess W. Bleeding by Bruton Tyrosine Kinase-Inhibitors:

1 ว			
2	182		Dependency on Drug Type and Discosse <i>Cancerg</i> Mar 4 2021:12(5)
4	402	4	Munir T. Prown IB. O'Prion S. et al. Final analysis from DESONATE: Up to
5	403	4.	within 1, Blown JK, O Bhen S, et al. Final analysis from RESONATE. Op to
0 7	484		six years of follow-up on forutinio in patients with previously treated chronic
8	485		lymphocytic leukemia or small lymphocytic lymphoma. American journal of
9	486	_	hematology. Dec 2019;94(12):1353-1363.
10	487	5.	Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-
11	488		cell malignancies (BRUIN): a phase 1/2 study. Lancet. Mar 6
13	489		2021;397(10277):892-901.
14	490	6.	Rogers KA, Thompson PA, Allan JN, et al. Phase II study of acalabrutinib in
15	491		ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic
16 17	492		leukemia. Haematologica. Sep 1 2021;106(9):2364-2373.
18	493	7.	Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study
19	494		of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's
20	495		macroglobulinemia. Cancer science. Sep 2020;111(9):3327-3337.
21	496	8.	Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib Versus Ibrutinib in
23	497		Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic
24	498		Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of
25	499		clinical oncology : official journal of the American Society of Clinical Oncology.
26 27	500		Feb 10 2023;41(5):1035-1045.
28	501	9.	Tam CS. Opat S. D'Sa S. et al. A randomized phase 3 trial of zanubrutinib vs
29	502		ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
30 21	503		<i>Blood</i> Oct 29 2020:136(18):2038-2050
31	504	10	Sved YY Zanubrutinib: First Approval Drugs Jan 2020:80(1):91-97
33	505	10.	Tam CS Munoz II. Seymour IF. Onat S Zanubrutinib: nast present and future
34	505	11.	Rlood cancer journal Sep 11 2023:13(1):141
35	507	12	Tam CS Onat S Simpson D et al. Zanubrutinib for the treatment of relansed
30 37	507	12.	or refractory mantle call lymphome. Blood advances Jun 22 2021:5(12):2577
38	500		of refractory manue cen tymphoma. <i>Bloba davances</i> . Juli 22 2021,5(12).2577-
39	510	12	2305. Song V. Zhay, K. Zay, D. et al. Treatment of Patients with Delenged on
40 41	510	13.	Song Y, Zhou K, Zou D, et al. Treatment of Patients with Relapsed of
41	511		Refractory Manue-Cen Lymphoma with Zanubrutino, a Selective Inhibitor of
43	512		Bruton's Tyrosine Kinase. Clinical cancer research : an official journal of the
44	513		American Association for Cancer Research. Aug 15 2020;26(16):4216-4224.
45 46	514	14.	Wolska-Washer A, Robak I. Zanubrutinib for the treatment of lymphoid
40 47	515		malignancies: Current status and future directions. Frontiers in oncology.
48	516		2023;13:1130595.
49	517	15.	Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and
50 51	518		rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic
52	519		lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. The Lancet.
53	520		Oncology. Aug 2022;23(8):1031-1043.
54	521	16.	Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors.
55 56	522		Hematology. American Society of Hematology. Education Program. Dec 4
57	523		2020;2020(1):336-345.
58	524	17.	Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of
59	525		zanubrutinib monotherapy in patients with B-cell malignancies. Blood advances.
60			

2			
3	526		Feb 22 2022;6(4):1296-1308.
4	527	18.	Beninger P, Murray M. Review of FDA Amendments Act Section 921
6	528		Experience in Posting Data-mining Results from the FAERS Database. <i>Clinical</i>
7	529		<i>theraneutics</i> . Feb 2021:43(2):380-395
8	530	19	Shu Y He X Liu Y Wu P Zhang O A Real-World Disproportionality Analysis
9 10	531	17.	of Olaparih: Data Mining of the Public Version of FDA Adverse Event
10	532		Penorting System Clinical anidemiology 2022:14:780-802
12	522	20	Lin D. He M. Vu V. He V. Vee W. Lin D. Deel world sefety of Leoosemide: A
13	555	20.	Liu F, He W, Au A, He I, I ao W, Liu B. Real-wolld safety of Lacosannue. A
14 15	534		pharmacovignance study based on spontaneous reports in the FDA adverse
15	535	0.1	event reporting system. Seizure. Aug 2023;110:203-211.
17	536	21.	Mazhar F, Battini V, Gringeri M, et al. The impact of anti-1NFalpha agents on
18	537		weight-related changes: new insights from a real-world pharmacovigilance
19	538		study using the FDA adverse event reporting system (FAERS) database. <i>Expert</i>
20 21	539		opinion on biological therapy. Sep 2021;21(9):1281-1290.
22	540	22.	Li Z, Zou W, Yuan J, Zhong Y, Fu Z. Gender differences in adverse events
23	541		related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse
24	542		event reporting system. Expert opinion on drug safety. Jul 31 2023:1-8.
25 26	543	23.	Song Y, Wu SJ, Shen Z, et al. Chinese expert consensus on Bruton tyrosine
20	544		kinase inhibitors in the treatment of B-cell malignancies. Experimental
28	545		hematology & oncology. Oct 16 2023;12(1):92.
29	546	24.	O'Brien SM. Brown JR. Byrd JC. et al. Monitoring and Managing BTK
30 21	547		Inhibitor Treatment-Related Adverse Events in Clinical Practice <i>Frontiers in</i>
32	548		oncology 2021:11:720704
33	549	25	Liang D Song Z Liu P Wang Z Zhao R A prediction model for severe
34	550	23.	hematological toxicity of BTK inhibitors <i>Annals</i> of <i>hematology</i> Oct
35	551		nonatological toxicity of DTR minotors. <i>Tunnus of nematology</i> . Oct $2023 \cdot 102(10) \cdot 2765(2777)$
30 37	557	26	2025,102(10).2705-2777. Esturiãón HV Doraläf A. Zain D. Smith CIE. Comparativo Analysis of DTV
38	552	20.	Inhibitors and Machanisma Underlying Adverse Effects (2206 624X (Drint))
39	555	27	Show has a mechanisms of defiying Adverse Effects. (2290-034X (PTIII)).
40	554	27.	Snatzei JJ, Olson SK, Tao DL, McCarty OJT, Danilov AV, DeLougnery TG.
41 42	222		Ibrutinib-associated bleeding: pathogenesis, management and risk reduction
43	556		strategies. Journal of thrombosis and haemostasis : JTH. May 2017;15(5):835-
44	557		847.
45	558	28.	Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet
46 47	559		immune receptors GPVI and CLEC-2. The Journal of clinical investigation. Jan
48	560		2 2019;129(1):12-23.
49	561	29.	May F, Hagedorn I, Pleines I, et al. CLEC-2 is an essential platelet-activating
50	562		receptor in hemostasis and thrombosis. <i>Blood</i> . Oct 15 2009;114(16):3464-3472.
51 52	563	30.	Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton's
53	564		Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Frontiers in
54	565		immunology. 2017;8:1454.
55	566	31.	Nocco S, Andriano TM, Bose A, et al. Ibrutinib-associated dermatologic
56 57	567		toxicities: A systematic review and meta-analysis. Critical reviews in
58	568		oncology/hematology. Jun 2022:174:103696
59	569	32	Wan O Li O Lai X Xu T Hu I Peng H Data mining and safety analysis of
60	507	54.	χ , $\Sigma_1 \chi$, $\Sigma_2 \chi$, $\Sigma_3 \chi$, $\Sigma_4 \chi$, $\Sigma_1 \chi$, $\Sigma_1 \chi$, $\Sigma_2 \chi$, $\Sigma_3 \chi$, $\Sigma_4 \chi$, $\Sigma_5 \chi$

1			
2			
3 ∕	570		BTK inhibitors: A pharmacovigilance investigation based on the FAERS
-+ -5	571		database. Frontiers in pharmacology. 2022;13:995522.
6	572	33.	de Sa Dias TC, Baby AR, Kaneko TM, Robles Velasco MV.
7	573		Relaxing/straightening of Afro-ethnic hair historical overview <i>Journal of</i>
8	574		assumption down at a local Mar 2007:6(1):2.5
9	574	24	Cosmetic dermatology. Mai 2007,0(1).2-3.
10	5/5	34.	Bitar C, Farooqui MZ, Valdez J, et al. Hair and Nail Changes During Long-term
 10	576		Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. JAMA
12	577		dermatology. Jun 1 2016;152(6):698-701.
14	578	35.	Opat S, Tedeschi A, Hu B, et al. Safety and efficacy of zanubrutinib in
15	579		relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA
16	580		study <i>Blood advances</i> Nov 28 2023:7(22):6801-6811
17	500	26	Soumarai ID Mate AR Degen A at al Zapubrutinih abinutuzumah and
18	500	50.	Soumeral JD, Mato AR, Dogan A, et al. Zanuorutinio, obinutuzuniao, and
19	582		venetoclax with minimal residual disease-driven discontinuation in previously
20	583		untreated patients with chronic lymphocytic leukaemia or small lymphocytic
21	584		lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology.
23	585		Dec 2021;8(12):e879-e890.
24	586	37	Zhang O Tao R Li Z et al A phase II study of Zanubrutinib in combination
25	587	27.	with rituyingh in patients with relansed/refractory aggressive and indolent B
26	500		with fituxiniab in patients with felapseu/feliactory aggressive and indofent B-
27	388		cell lymphoma. Leukemia & lymphoma. Oct 2022;63(10):2503-2506.
28	589	38.	Allan JN, Helbig D, Mulvey E, et al. Zanubrutinib and Venetoclax As Initial
29	590		Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients
30	591		with Minimal Residual Disease Positivity (BruVenG). Blood. 2023/11/02/
32	592		2023-142-3285
33	503	30	Geng H. Jia S. Zhang V. et al. Efficacy and safety of zanubrutinih plus R-CHOP
34	504	57.	in treatment of non CCD DI DCL with extremedial involvement. Executions in
35	594		in treatment of non-OCB DLBCL with extrahodar involvement. <i>Frontiers in</i>
36	595		immunology. 2023;14:1219167.
3/	596		
30	570		
40			
41	597		
42			
43	598		
44			
45	599		
46			
47			
49			
50			
51			
52			
53			
54 55			
55 56			
57			
58			
59			

600 Figure titles and legends

- 601 Figure 1. Forest plot of the AEs for zanubrutinib at the System Organ Class Level. SOC,
- 602 system organ class; CI, confidence interval.
- 603 Figure 2. Forest plot of the top 25 AE risk signals for zanubrutinib. PT, preferred term;
- 604 ROR, reported odds ratio; CI, confidence interval.
- 605 Figure 3. Time to onset of zanubrutinib-related AEs.
- 606 Figure 4. Volcano plots of the difference in PT signals for the combination analysis. A:
- 607 Zanubrutinib+Rituximab VS. Zanubrutinib alone. B: Zanubrutinib+ Chemotherapy VS.

teliezoniz

608 Zanubrutinib alone. ROR, reported odds ratio; PT, preferred term.

611

20

21

22 23

24

25

26 27

28

29

30

31

32

33

34

35

36

37

43

44 45 46

BMJ Open Table 1. Characteristics of reports associated with Zanubrutinib Zanubrutinib Zanubrutinib+ Rituximab Zanubrutinib+ Chemotherapy n (%) n (%) Table titles and legends to text and for the superior of the superior o n (%) n (%) Number of reports 848 166 Number of adverse events 2826 603 Sex Female 8 (0.9%) 30 (18.1%) Male 19 (2.2%) 49 (29.5%) 0 m.5 (6.4%) 3 (16.7%) Missing 821 (96.8%) 87 (52.4%) Al training, and similar technologies. Age(years) 3 (0.4%) 1 (0.6%) ≥86 65~85 14 (1.7%) 27 (16.3%) 18~64 4 (0.5%) 35 (21.1%) Missing 827 (97.5%) 103 (62.0%) **g**0 (76.9%) June 79 (11.5%) Outcomes 64 (7.5%) 8(4.8%) Death **23** (3.8%) at 9(24.4%) Life-threatening 15 (1.8%) 3(1.8%) Hospitalization 218 (25.7%) 25(15.1%) Agence 0 Disability 7 (0.8%) 2(1.2%) **Congenital Anomaly** 1 (0.1%) 0 Bibliographique **Required intervention** 2 (0.2%) 0 0

del

|--|

		mjopen-2024-08499 J by copyright, inclu	
Other Serious	176 (20.8%)	96(57.8%)	<u>di</u> <u>9</u> 19(24.4%)
Missing	365 (43.0%)	32(19.3%)	of 26 (27.7%)
Reporter's Occupation			US est
Consumer	342 (40.3%)	8 (4.8%)	reig 7 (9.0%)
Health professional 📃 📐	122 (14.4%)	64 (38.6%)	at new 26 (59.0%)
Physician	280 (33.0%)	84 (50.6%)	
Pharmacist	95 (11.2%)	9 (5.4%)	¥₽ ₩ 8 ₩ 8 8 (10.3%)
Missing	9 (1.1%)	1 (0.6%)	and e cad 2 (2.6%)
Reporter Countries	Un		ed fr data
USA	523 (61.7%)	15 (9.0%)	
China	141 (16.6%)	103 (62.0%)	nie s nie 2 (53.8%)
Australia	52 (6.1%)	36 (21.7%)	≥ a7 (21.8%)
Canada	29 (3.4%)	1 (0.6%)	trair <mark>j</mark> o 0
Others	103 (12.2%)	11(6.7%)	1 (14.1%)
			nj.com/ on June 7, 2025 at Agence Bibliographi and similar technologies.
For p	peer review only - http:	//bmjopen.bmj.com/site/about/gui	delines.xhtml de

Page 29 of 40		BMJ Ope	en	ses re	
SOC	Ν			202/ latec	ROR(95% CI)
¹ Injury, poisoning and procedural complications	471			to nent	1.46(1.32-1.61)
² General disorders and administration site conditions	390	H H -1		t Su	0.74(0.67-0.83)
J Investigations	244		H	t ar	1.51(1.32-1.72)
5 Infections and infestations	240			nd d	1.57(1.38-1.79)
6 Skin and subcutaneous tissue disorders	238			lata	1.61(1.41-1.84)
7 Gastrointestinal disorders	222	·		mi BE	1.01(0.88-1.16)
8 Nervous system disorders	143			ning	0.68(0.57-0.8)
9 10 Respiratory, thoracic and mediastinal disorders	130			9, A	1.02(0.86-1.22)
10 11 Blood and lymphatic system disorders	129	i i i			- 2.78(2.33-3.32)
12 Musculoskeletal and connective tissue disorders	128	⊢_ ∎+		aini ope	0.87(0.73-1.04)
13 Cardiac disorders	72			ng,	1.3(1.03-1.65)
14 Vascular disorders	60	· · · · · · · · · · · · · · · · · · ·	 	ang	1.15(0.89-1.48)
15 Renal and urinary disorders	53	· · · · · · · · · · · · · · · · · · ·		si on	0.97(0.74-1.28)
10 17 Neoplasms benign, malignant and unspecified (incl cysts and	l polyps) 51	-		mila	0.41(0.31-0.54)
18 Psychiatric disorders	49	H 		ar te	0.3(0.23-0.4)
19 Surgical and medical procedures	49			ane	1.22(0.92-1.62)
20 Metabolism and nutrition disorders	47	· · · · · · · · · · · · · · · · · · ·		10k	0.87(0.65-1.16)
21 Eye disorders	34			2022 Dgie	0.63(0.45-0.88)
22 23 Hepatobiliary disorders	20	· · · · · · · · · · · · · · · · · · ·		s. at	0.88(0.57-1.36)
24 Ear and labyrinth disorders	15	▶ <u> </u>	-	Ag	1.3(0.78-2.16)
25 Immune system disorders	13			enc	0.4(0.23-0.69)
26 Product issues	10 🛏	⊨⊸i l		e B	0.19(0.1-0.36)
²⁷ Reproductive system and breast disorders	9			i i i i i i i i i i i i i i i i i i i	0.51(0.26-0.98)
28 Social circumstances	4 🛏			ogr	0.3(0.11-0.79)
30 Congenital, familial and genetic disorders	3 ⊢	-	-	aph	0.39(0.13-1.21)
31 Endocrine disorders	2			iqu	0.27(0.07-1.09)
32 33 24	0 For peer review	v only - http://bmjopen.bm	nj.com/site/about/guidelin	es.xhtml e 3	4

РТ		BMJ Open	ROR(95% CI) p	Zanubrutinib(N)	Others(N)
Haemorrhage subcutaneous			190.8(128-284.5) s	25	867
Penile haemorrhage	—		112.6(35.9-352.6)	3	175
Petechiae			40.7(24.8-66.5)	16	2596
Blood blister	—		40.3(16.7-97.2) 40.3	5	815
Meningitis cryptococcal	—		40.1(12.9-12499) 40.1	3	491
Ecchymosis	—		igi 22 34.6(17.3-69.∰) ⊒i 68	8	1521
Haemorrhagic diathesis	—		29.7(11.1-79.2) 29.7	4	886
Pneumonia fungal	•		23.7(10.6-53 6	6	1661
Hepatitis B	—		21.8(8.2-58.3%) 21.8(8.2-58.3%)	4	1203
Myelosuppression	•		reigner 19.7(14.4-27. هو 19.7) 19.7(14.4-27.	39	13143
Contusion	•		17.2(13.5-21.9) 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	68	26538
White blood cell count increased	•		¥ جَ عَ 16.1(10.6-24.هُ) و مَ المُ	22	9042
Hypernatraemia	◆		dat Afro 15(4.8-46.6) 15(4.8-46.6)	3	1314
Increased tendency to bruise	• -		13.7(5.7-33.1 3.9	5	2392
Hepatitis B reactivation	•		13.1(4.2-40.7	3	1504
Blood urine present	•		ain open 12.7(6.6-24.4	9	4664
Tumour lysis syndrome	•		11.1(4.6-26.8	5	2949
Haemolysis	←		11.1(3.6-34.4	3	1779
Purpura	←		10(3.2-31.1) 10	3	1964
Atrioventricular block	←		ر آن 9.9(3.2-30.8 و 9.9 202	3	1988
Subdural haematoma	•		9.7(4-23.4) 9.7	5	3381
Eye haemorrhage	•		9.7(4-23.2) gen 9.7(4-23.2) gen	5	3400
Haemoglobin abnormal	←		9.5(3.1-29.6)	3	2066
Intestinal perforation	•		9.5(3.6-25.4) ອ	4	2764
				- 7	6024











Supplementary

Table S1. Formulas and signal detection criteria for ROR.

Formula	Signal standard
ROR = (ad/bc)	 Lower limit of ROR95%CI>1;
	· a≥3
$ROR95\%CI = e^{\ln(ROR) \pm 1.96\sqrt{(\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d})}}$	-

a: number of specific adverse events to the target drug; b: number of other adverse events to the target drug; c: number of specific adverse events to background drugs; d: number of other adverse events to the background drug;

ROR: reporting odds ratio, CI: confidence interval

2
3
1
4
5
6
7
8
0
9
10
11
12
12
13
14
15
16
17
17
18
19
20
21
22
22
23
24
25
26
20
27
28
29
30
21
31
32
33
34
25
22
36
37
38
30
10
40
41
42
43
11
44
45
46
47
48
40
49
50
51
52
52
55
54
55
56
57
50
20
59

1

Table S2. All positive Preferred Terms associated with Zanubrutinib.

SOC	РТ	n	ROR (95%CI)
	Myelosuppression	39	19.7 (14.4-27.1)
	Febrile neutropenia	14	4.4 (2.6-7.4)
	Neutropenia	13	1.8 (1-3)
disorders	Increased tendency to bruise	5	13.7 (5.7-33.1)
	Haemorrhagic diathesis	4	29.7 (11.1-79.2)
	Cytopenia	4	5.2 (1.9-13.8)
	Haemolysis*	3	11.1 (3.6-34.4)
	Atrial fibrillation	21	4.9 (3.2-7.6)
Condias disenders	Pericardial effusion*	7	7.4 (3.5-15.5)
Cardiac disorders	Atrioventricular block	3	9.9 (3.2-30.8)
	Ventricular tachycardia	3	5 (1.6-15.5)
Ear and labyrinth disorders	Ear discomfort*	3	6.9 (2.2-21.5)
Eye disorders	Eye haemorrhage	5	9.7 (4-23.2)
	Dysphagia	14	4 (2.4-6.8)
	Dyspepsia*	8	2.1 (1-4.2)
Contraintenting1 discardors	Intestinal perforation*	4	9.5 (3.6-25.4)
Gastrointestinal disorders	Faeces discoloured	3	3.8 (1.2-11.7)
	Haematemesis	3	3.3 (1.1-10.2)
	Tooth disorder*	3	3.2 (1-10.1)
	Fatigue	50	1.4 (1-1.8)
	Asthenia	30	2 (1.4-2.9)
General disorders and	Peripheral swelling	18	2 (1.3-3.2)
administration site conditions	Oedema peripheral	12	3.4 (1.9-5.9)
	Oedema	5	2.6 (1.1-6.3)
	Mass*	3	4.9 (1.6-15.2)
Hepatobiliary disorders	Hepatic function abnormal	5	3.2 (1.3-7.6)
	Urinary tract infection	19	2.4 (1.6-3.8)
	Infection	15	2.2 (1.3-3.6)
	Cellulitis	10	4.8 (2.6-8.9)
	Sepsis	9	2 (1-3.8)
Infections and infestations	Pneumonia fungal	6	23.7 (10.6-53)
Infections and infestations	Hepatitis B	4	21.8 (8.2-58.3)
	Meningitis cryptococcal	3	40.1 (12.9-124.9)
	Hepatitis b reactivation	3	13.1 (4.2-40.7)
	Pneumocystis jirovecii pneumonia	3	5.5 (1.8-17.2)
	Skin infection	3	5.4 (1.7-16.8)
Injury, poisoning and	Contusion	68	17.2 (13.5-21.9)
procedural complications	Subdural haematoma	5	9.7 (4-23.4)
Investigations	Platelet count decreased	29	5.7 (4-8.3)
in , congutono	White blood cell count decreased	24	4.4 (2.9-6.6)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	White blood cell count increasedHaemoglobin decreased		16.1 (10.6-24.5)
			3.4 (2-5.8)
	Blood urine present	9	12.7 (6.6-24.4)
	Blood creatinine increased	8	3 (1.5-6.1)
	Red blood cell count decreased	6	4.4 (2-9.7)
	Haemoglobin abnormal	3	9.5 (3.1-29.6)
	Blood iron decreased*	3	4.7 (1.5-14.7)
Matchalians and mutuition	Tumour lysis syndrome	5	11.1 (4.6-26.8)
disorders	Hypernatraemia*	3	15 (4.8-46.6)
disorders	Increased appetite*	3	4.7 (1.5-14.7)
Musculoskeletal and	Musculoskeletal pain	4	2.8 (1.1-7.6)
connective tissue disorders	Haemarthrosis	3	4.7 (1.5-14.7)
Namana angtan diasadan	Hypersomnia*	4	3.3 (1.2-8.8)
Nervous system disorders	Haemorrhage intracranial	3	6.3 (2-19.6)
Renal and urinary disorders	Haematuria	8	5.9 (3-11.9)
	Dysuria	5	3.5 (1.4-8.3)
Reproductive system and	Penile haemorrhage	3	112.6 (35.9-
breast disorders	Disurgi offusion	14	(2, (2, 7, 10, 5))
Respiratory, thoracic and	Frietania	14	0.2(3.7-10.3)
mediastinal disorders	Epistaxis	8	2.7(1.3-3.4)
	Sinus disorder	4	4.4 (1.6-11.7)
	Kasn	48	2.4 (1.8-3.2)
	Patenting Subcutaneous	25	190.8 (128-284.5
	Petechiae	10	40.7 (24.8-66.5)
	Skin discolouration*	10	5.1 (2.7-9.5)
	Rash macular	9	5.8 (3-11.2)
Skin and subcutaneous tissue	Ecchymosis	8	34.6 (17.3-69.4)
disorders	Night sweats	6	4.5 (2-10)
	Rash pruritic	6	2.8 (1.2-6.2)
	Blood blister	5	40.3 (16.7-97.2)
	Skin lesion	4	3.1 (1.2-8.4)
	Purpura	3	10 (3.2-31.1)
	Hair texture abnormal*	3	4.9 (1.6-15.2)
	Skin haemorrhage	3	4.6 (1.5-14.3)
Vascular disorders	Haemorrhage	18	4.4 (2.7-6.9)

* unexpected adverse event

SOC, system organ class; PT, preferred term; ROR, reporting odds ratio; CI, confidence interval.
Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PT	n	ROR (95%CI)
Mantle cell lymphoma		
Haemorrhage subcutaneous	4	32.2 (9.4-110.3)
Chest pain	Chest pain 5 7.6 (3.	
White blood cell count increased	4	7.0 (2.5-20.0)
Myelosuppression	6	5.1 (2.2-11.9)
Contusion	8	4.8 (2.3-9.9)
Pain	6	4.2 (1.8-9.6)
Dizziness	7	4.1 (1.9-8.9)
Oedema peripheral	3	3.7 (1.1-11.8)
Dyspnoea	11	3.6 (2.0-6.7)
Peripheral swelling	5	3.5 (1.4-8.6)
Platelet count decreased	10	3.2 (1.7-6.0)
Asthenia	7	2.7 (1.3-5.9)
Nausea	7	2.7 (1.2-5.7)
Rash	11	2.6 (1.4-4.8)
Chronic lymphocytic leukemia or small ly	mphocytic lympho	oma
Haemorrhage subcutaneous	8	41.3 (19.0-89.6
Atrioventricular block	3	26.7 (7.9-90.4)
Skin infection	3	6.9 (2.2-21.8)
Haematochezia	3	6.0 (1.9-19.1)
Blood creatinine increased	5	6.0 (2.4-14.6)
Petechiae	4	4.0 (1.5-10.8)
Erythema	6	3.7 (1.6-8.3)
Rash pruritic	3	3.5 (1.1-11.1)
Pericardial effusion	3	3.5 (1.1-10.8)
Contusion	21	3.4 (2.2-5.3)
Visual impairment	3	3.4 (1.1-10.5)
Skin discolouration	3	3.2 (1.0-9.9)
Anxiety	5	3.1 (1.3-7.6)
Dehydration	6	3.1 (1.4-6.9)
Cardiac failure	4	3.0 (1.1-8.1)
White blood cell count increased	13	2.9 (1.7-5.1)
Abdominal discomfort	5	2.9 (1.2-7.0)
Waldenström's macroglobulinemia		
Haemorrhage subcutaneous	8	46.6 (12.3-175.9
Drug-induced liver injury	3	10.4 (2.5-43.6)
Petechiae	8	8.7 (3.7-20.5)
Vertigo	3	8.7 (2.2-34.8)
Eye haemorrhage	4	7.7 (2.4-25.1)
Blood urine present	4	6.3 (2.0-19.9)
Blood blister	4	58(19-180)

Table S3. Subgroup Disproportionality Analysis by Indications

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Sinus disorder	3	5.8 (1.6-21.4)
Depressed mood	3	5.2 (1.4-19.0)
Gait inability	3	4.7 (1.3-17.0)
Cellulitis	4	4.3 (1.5-13.0)
Gastroesophageal reflux disease	4	4.3 (1.5-13.0)
Musculoskeletal stiffness	3	4.3 (1.2-15.4)
Night sweats	3	3.7 (1.1-13.0)
Erythema	5	3.6 (1.4-9.5)
Rash	18	3.4 (2.0-5.6)
Abdominal discomfort	4	3.3 (1.1-9.7)
Contusion	25	3.0 (1.9-4.6)
Pruritus	7	2.8 (1.3-6.3)

Table S4. Subgroup Disproportionality Analysis Results in the United States and China

РТ	n	ROR (95%CI)
United States		
Haemorrhage subcutaneous	18	601.7 (369.4-980.3)
Penile haemorrhage	3	176.1 (55.7-556.1)
Petechiae	16	87.7 (53.4-143.9)
Ecchymosis	6	62.3 (27.8-139.4)
Haemorrhagic diathesis	4	51.1 (19.1-136.8)
Hypernatraemia	3	44.8 (14.4-139.8)
Blood blister	5	44.8 (18.6-108.1)
Pneumonia fungal	3	30.1 (9.7-93.8)
Procedural haemorrhage	3	22.7 (7.3-70.5)
Contusion	67	21.6 (17.0-27.6)
Blood urine present	9	16.5 (8.6-31.9)
White blood cell count increased	13	15.8 (9.2-27.3)
Eye haemorrhage	5	15.2 (6.3-36.7)
Increased tendency to bruise	5	13.5 (5.6-32.6)
Subdural haematoma	3	10.7 (3.5-33.3)
Ear discomfort	3	8.4 (2.7-26.0)
Haematuria	6	8.3 (3.7-18.4)

2			
3	Cardiac operation	3	8.2 (2.7-25.5)
4	Skin infection	3	8.1 (2.6-25.3)
6	Platelet count decreased	22	7 2 (4 7-10 9)
7	Mass	3	7.1(2.3-22.0)
8	Plood iron docrossed	3	6.6(2.1,20.5)
9	Device and in a final and	3	0.0(2.1-20.3)
10	Pericardial effusion	3	0.0 (1.9-18.5)
12	Musculoskeletal pain	4	5.9 (2.2-15.7)
13	Rash macular	9	5.7 (3.0-11.1)
14	Faeces discoloured	3	5.6 (1.8-17.4)
15	Night sweats	5	5.4 (2.3-13.1)
10	Increased appetite	3	5.4 (1.7-16.8)
18	Haemorrhage	16	5.3 (3.3-8.7)
19	Dysphagia	12	5.1 (2.9-9.0)
20	Oedema	5	5.0 (2.1-12.0)
21	Skin haemorrhage	3	5.0 (1.6-15.5)
23	Skin discolouration	9	4.9 (2.6-9.4)
24	Red blood cell count		× ,
25	decreased	5	4.7 (2.0-11.3)
26	Pleural effusion	5	47(20-113)
27 28	A trial fibrillation	14	4.7(2.011.3) 4.7(2.8-7.9)
29	Sinus disordar	14	4.7(2.0-7.9)
30		4	4.0(1.7-12.2)
31	Haemoglobin decreased	11	4.5 (2.5-8.1)
32	Skin lesion	3	4.5 (1.4-13.9)
34	Joint injury	3	4.2 (1.4-13.2)
35	Oedema peripheral	7	4.1 (1.9-8.6)
36	Tooth disorder	3	4.0 (1.3-12.3)
37	Hair texture abnormal	3	3.9 (1.3-12.1)
30	Cellulitis	5	3.7 (1.5-8.9)
40	White blood cell count	15	27(2261)
41	decreased	15	5.7 (2.2-0.1)
42	Hypersomnia	4	3.7 (1.4-9.8)
43 44	Localised infection	3	3.5 (1.1-10.8)
45	Depressed mood	5	3.4 (1.4-8.2)
46	Rectal haemorrhage	3	3.4 (1.1-10.6)
47	Dysuria	3	3 3 (1 1-10 2)
48	Blood creatinine increased	5	33(14-78)
50	Neck pain	5	3.5(1.47.0) 3.1(1.3.74)
51	Productive cough	3	3.1(1.3-7.4)
52	Productive cough	4	3.1(1.2-6.2)
53	Rash pruriuc	5	2.9 (1.2-0.9)
54 55	Stomatitis	5	2.7 (1.1-6.5)
56	Intection	11	2.7 (1.5-4.9)
57	Dyspepsia	8	2.6 (1.3-5.2)
58	Urinary tract infection	15	2.5 (1.5-4.2)
59 60	Neutropenia	9	2.4 (1.3-4.7)
00			

Rash	40	2.4 (1.7-3.3)
Myalgia	10	2.4 (1.3-4.4)
Asthenia	24	2.4 (1.6-3.5)
Abdominal distension	7	2.3 (1.1-4.9)
Dehydration	8	2.2 (1.1-4.4)
Hypertension	11	2.1 (1.2-3.8)
Peripheral swelling	13	1.9 (1.1-3.3)
Fatigue	49	1.7 (1.3-2.3)
Cough	16	1.7 (1.01-2.7)
China		
Haemolysis	3	44.8 (13.8-145.0)
Hepatitis B	3	40.0 (12.4-129.1)
Tumour lysis syndrome	3	31.3 (9.8-100.3)
Haemorrhage subcutaneous	6	22.3 (9.8-50.6)
White blood cell count	8	19.9 (9.8-40.6)
Pericardial effusion	3	93(30-291)
Peripheral swelling	3	7 9 (2 5-24 9)
Pleural effusion	5	7.5 (3.1-18.2)
Febrile neutropenia	3	64(2,1-20,1)
Covid-19	3	6.0 (1.9-18.9)
Sensis	3	5 4 (1 7-17 0)
Oedema peripheral		5.1 (1.9-13.7)
Interstitial lung disease	3	45(14-140)
Myelosuppression	30	4.3(1.4-14.0)
wyelosuppression		5.4 (2.3-4.6)

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.





Figure S1. The flow diagram of screening zanubrutinib-related AEs from the FAERS database. DEMO, demographic and administrative information; DRUG, drug information; REAC, adverse event information; PT, preferred term.

Important Medical Event	N		ROR(95%
Meningitis cryptococcal	3	1	40.12(12.8
Pneumonia fungal	6	· · · · · · · · · · · · · · · · · · ·	23.74(10.6
Hepatitis B	4	· · · · · · · · · · · · · · · · · · ·	21.84(8.18
Myelosuppression	39		19.72(14.3
Hepatitis B reactivation	3		13.1(4.22-
Tumour lysis syndrome	5		11.14(4.63
Haemolysis	3		11.07(3.5)
Subdural haematoma	5		9.72(4.04-
Intestinal perforation	4		9.5(3.56-2
Pericardial effusion	7		7.38(3.51
Haemorrhage intracranial	3		6.31(2.03-
Pneumocystis jirovecii pneumonia	3		5.54(1.79-
Cytopenia	4		5.19(1.94-
Ventricular tachycardia	3	▶	5(1.61-15
Atrial fibrillation	21	HEH CONTRACTOR OF	4.93(3.21-
Haemarthrosis	3	} →	4.75(1.53-
Febrile neutropenia	14		4.39(2.6-7
Haematemesis	3		3.28(1.06-
Sepsis	9		1.97(1.03-
Neutropenia	13		1.77(1.02-

Figure S2. Forest plot of the important medical event signals for zanubrutinib. ROR, reported odds ratio; CI, confidence interval.